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Abstract 
B cells are known to contribute to and/or influence immune response trough a 
variety of mechanisms. Regulatory B cells (Bregs) have recently discovered and 
their role in regulating autoimmune diseases has been demonstrated in different 
murine models. In the context of transplantation B cells are generally thought to 
promote graft rejection through the production of alloantibody and their capacity 
to efficiently present alloantigens. However, recent clinical trials with B cell 
depletion have suggested that B cells contribute to the regulation of immune 
responses to grafts. In addition the evidence that renal transplant patients that 
are tolerant to the graft have an expansion of B cells with a regulatory 
phenotype further confirm this idea.  
The hypothesis tested during this PhD is that murine regulatory B cells, defined 
as transitional-2 marginal zone precursor (T2-MZP), are contributing to 
transplantation tolerance. The aims of this project are: i) to investigate whether 
T2-MZP can transfer transplantation tolerance; ii) to analyse whether the 
expression of Galectin-1 (Gal-1), known to be a functional molecule for Tregs, is 
necessary for T2-MZP to suppress; iii) to study whether an increase in T2-MZP 
is observed in tolerant mice like what has been shown in tolerant transplant 
patients. 
The results obtained during this PhD have demonstrated that T2-MZP purified 
from naïve mice were unable to regulate the immune responses to graft 
antigens both in vitro and in vivo. However, their regulatory capacity was 
observed when T2-MZP were purified from mice kept in the conventional (CV) 
area of the animal house although IL-10 was not involved in their regulatory 
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capacity. A difference in the gut flora between mice kept in the Specific-
pathogen-Free (SPF) and CV areas was observed and maybe responsible for 
the differences in the T2-MZP functions. Moreover, Gal-1 was confirmed to be 
expressed by B cells and T2-MZP isolated from Gal-1-/- mice kept in the CV 
area lost the ability to suppress in vitro CD4+ T cell activation and to prolong 
skin graft survivals, suggesting that Gal-1 has a functional role in B cell 
suppressive function. One of the hypotheses was that the absence of Gal-1 
influences the response of B cells to gut. Gal-1-/- B cells showed reduced IL-10 
production and increased up-regulation of activation markers in response to a 
variety of Toll-like receptor ligands in comparison to wild-type B cells, and 
showed differences in the percentage of P38, ERK phosphorylation and NF-κB 
translocation. Finally, in trying to mimic the findings with renal transplant 
patients, mice were rendered tolerant to skin transplants using in vivo anti-
CD40L (MR1) and donor splenocyte transfusion (DST). The number of T2-MZP 
increased in these mice and these cells were suppressive in vitro and, as 
before, their regulatory capacity did not appear to correlate with IL-10 
production. Once transferred in vivo T2-MZP isolated from tolerant mice, and 
not animal rejecting an allograft, induced prolongation of skin transplants onto 
naïve recipients. 
These observations indicate that T2-MZP play a role in transplant tolerance, 
they need to be “primed” either during tolerance induction protocol or by 
interaction with gut flora and that Gal-1 is a functional molecule for B cells and 
T2-MZP B cells.  
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1.1 Transplantation & Rejection 
1.1.1 General introduction 	  
Transplantation is currently the treatment of choice for end stage organ failure 
[1,2].  Damage to the transplanted organ is initiated by ischemia/reperfusion 
injury associated with the transplant procedure [1,2]. These injuries lead to the 
activation of the adaptive immune system, which will result in either acute or 
chronic rejection [1,2]. Transplanted organs can be rejected by the recipient’s 
adaptive immune system through direct, indirect and semi-direct pathways [1]. 
When grafts are rejected by the direct pathway allo-MHC class I or class II, 
expressed by donor antigen-presenting cells (APCs), is directly recognized by 
recipient T cells (CD4+ and CD8+ T cells). This pathway is mainly associated to 
acute rejection [1]. Once the APC transplanted with the graft disappeared from 
the circulation, recipient APCs that migrate to the graft, take up and process 
alloantigens and then display them in the context of self MHC to CD4 and CD8 
T cells in the peripheral lymphoid organs (the indirect pathway). This pathway 
contributes to chronic rejection [1]. Subsequently, the graft gets destroyed via 
the activated CD4 and CD8 T cells [1]. In the semi-direct pathway, membrane 
components (MHC) of donor APCs are transferred to recipient APCs via cell-
cell contact or via exsome fusion and presented on the recipient APCs both as 
intact MHC promoting direct pathway and as processed peptide promoting the 
indirect pathway [1,2]. This pathway allows the presentation of alloantigens on 
the same APC via direct and indirect pathways [1,2]. The existence of this 
pathway suggests that the direct pathway never goes to sleep [1,2]. 
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1.1.2 Types of rejection 
Hyper-acute rejection 	  
Hyper-acute rejection is an immediate rejection, which is mainly mediated by 
previously existing antibodies against donor antigens [1]. The presence of 
alloantibody in the recipient is usually due to prior blood transfusion, pregnancy 
or earlier transplant [1]. In this type of rejection the binding of the pre-existing 
alloantibodies to transplanted organ blood vessel endothelial cells, and the 
subsequent activation of the complement system, results in inflammation and 
blood coagulation that cause rapid rejection [1,3]. 
Acute rejection 	  
Acute rejection is the result of recipient T cell recognition of donor MHC on 
donor DCs that have migrated from the graft to the draining lymph node [3]. 
Once T cells are activated they move from the lymph nodes to the graft and 
initiate the rejection largely through cytotoxic T cells [3]. This rejection mainly 
occurs via the direct pathway, but the indirect pathway can also be involved [3]. 
This process of rejection requires one day to a few weeks to occur [3]. 
Chronic rejection 	  
Chronic rejection occurs within months to years post-transplant [4]. Chronic 
rejection can be due to alloantigen-dependent events or/and antigen-
independent factors [5]. Alloantigen-dependent chronic rejection is mainly a 
consequence of early episodes of acute rejection that lead to chronic rejection 
[6]. Ongoing episodes of acute rejection result in a continuously activated 
immune response that may gradually accelerate the process of indirect 
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alloantigen presentation that might in turn increase the magnitude of the 
rejection process [7]. Antigen-independent factors include injuries associated 
with transplantation, such as ischemia/reperfusion injury [6]. 
Ischemia/reperfusion injury activates resident macrophages to release 
inflammatory cytokines resulting in endothelial cell (EC) activation [8]. Activated 
EC mediate the expression of several molecules such as chemokines, adhesion 
molecules and MHCs on the donor graft EC [8,9,10]. This results in leukocyte 
recruitment, activation and infiltration into the allograft [8,11,12]. 
1.1.3 Cells involved in transplant rejection 
Innate immunity 	  
T cells are the key player in allograft acute rejection [13,14,15]. However, it is 
now well established that prior to alloantigen recognition by T cells pro-
inflammatory mediators are released into the allograft [13,14,15]. This initial 
response against the allograft is driven by the innate immune system and not 
adaptive immune system [13,14,15]. Dendritic (DCs) cells, macrophages, 
neutrophils and NK cells are innate immune system cells that detect pathogen 
derived molecules from inherently non-sterile grafts, such as skin, and 
molecules released from damaged and stressed host tissue through Pathogen-
recognition receptors (PRRs) [16,17,18]. PRRs are comprised of a number of 
different receptors, notably including Toll-like receptors (TLRs), which detect 
conserved sequences commonly associated with bacterial or viral molecules 
[16,17,18]. Upon activation of cells through their PRRs a cascade of signaling 
occurs leading to the activation of the transcription factor nuclear factor (NF)-κB 
and activator protein-1 (AP-1) [19], and the production of chemokines, pro-
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inflammatory cytokines and up-regulation of MHC I, MHC II and co-stimulatory 
molecules on the surface of APCs [19,20]. 
A) Dendritic cells  	  
In the absence of danger signals and activating antigens, DCs would remain 
immature in the periphery [22,23,24]. Although transplantation triggers DCs 
maturation the stimuli responsible for this are not yet known [21]. Once DCs 
become activated they mature and produce inflammatory cytokines and up-
regulate their expression of their co-stimulatory molecules and chemokine 
receptors, which induce their migration into secondary lymphoid organs, where 
they stimulate T cell responses [22,23,24]. It has been reported that the 
interaction between immature DCs and T cells results in T cells anergy or 
apoptosis [25]. Given this fact, many researchers have taken an interest in 
using immature or toleragenic DCs (DCs that deliver inadequate co-stimulatory 
signals while presenting antigens to antigen-specific T cells [25]) as a therapy to 
induce peripheral tolerance [22,23,24]. 
B) Macrophages 	  
Although macrophages are not involved in direct initiation of allograft 
recognition, they mediate allograft damage through various mechanisms such 
as the release of pro-inflammatory cytokines, reactive nitrogen and oxygen 
species, phagocytosis of necrotic debris, and amplifying T cell responses via 
antigen presentation [26,27]. 
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C) Neutrophils 	  
Neutrophils migrate into transplanted organs within hours of surgery as a result 
of the trauma caused by the transplant procedure. Neutrophils damage the 
tissue via a variety of cytotoxic and pro-inflammatory mechanisms such as the 
release of cytokines and chemokines including IL-1, IL-12, TNF-α, CXCL8 and 
VEGF [28]. 
D) Natural Killer cells 	  
Despite the fact that NK cells are not able to cause allograft rejection on their 
own, they can amplify the magnitude of graft rejection at early stages of the 
alloresponse and help allo-reactive T cells and DCs exert their functions 
[29,30,31,32]. 
E) Complement 	  
Complement can be activated through three main pathways: the classical 
pathway, the lectin pathway and the alternative pathway [33]. Antigen-antibody 
complexes on pathogen/allograft cell surfaces trigger the classical pathway, 
whereas the lectin pathway involves the interaction of mannan-binding lectin 
with microbial surfaces [33]. C3b, a product of the activated classical pathway, 
initiates the alternative pathway [33]. Complement is mainly produced in the 
liver but can be produced locally by many cell types at the site of inflammation 
[34]. In transplantation, complement mainly contributes to antibody-dependent 
mechanisms of rejection, and can cause direct damage via the release of 
activation products such as C3b, C5b-9, C3a and C5a [35,36]. IgG or IgM 
bound on the allograft endothelium can activate complement through their 
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interaction with C1q [4]. C1q fixation by IgG or IgM induces conformational 
changes in C1q that subsequently allows C1r cleavage and the activation of 
C1s (C1q, C1r and C1s are C1 components) [4]. C1r acts as an enzyme that 
activates C2 and C4 [4]. Activated C4 breaks into two fragments C4a (small 
fragment) and C4b (large fragment) [4]. Next, C4b forms a complex with C2a 
(the classical pathway C3 convertase) [4]. This complex in turn activates C3 to 
cleave into C3a and C3b [4]. At this point, C3b joins the C4b-C2a complex and 
forms a complex that cleaves C5 into C5a and C5b [4]. Finally, C5b induces the 
formation of the membrane-attack complex (MAC) [4]. MAC is composed of 
C5b-C6-C7-C8-C9 (C5b-9) and binds to the cell membrane causing cell lysis 
[4]. Complement fixation contributes mainly in the pathogenesis of acute and 
hyper-acute rejection [37]. 
Adaptive immunity 
A) CD4 T cells 	  
CD4+ T cells, once activated, differentiate into T helper (Th) 1, Th2, Th17 or 
regulatory T cells (Tregs) [38]. CD4+ T cell subsets are characterized by the 
cytokines they produce and the transcription factors they express [39]. 
Th1 & Th2 	  
Th1 CD4+ T cells are characterized by the production of TNF-α, IFN-γ and IL-2 
and the expression of T-bet [40]. Allograft rejection mediated via Th1 CD4+ T 
cell responses is mainly by supporting cytotoxic T cell activation, and delayed 
type hypersensitivity reaction mediated by IFN-γ [41,42,43]. Whereas, Th2 
CD4+ T cells are defined by the production of IL-4, IL-5, IL-6, IL-9 and IL-13 
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[40]; through IL-4 and IL-5 they recruit eosinophils leading to allograft rejection 
[44,45].  
Th17 & Tregs  	  
Th17 CD4+ T cells are characterized by the production of IL-17-A and IL-17-F, 
and the expression of retinoic acid-related orphan receptor-α (RORα) and 
retinoic acid-related orphan receptor γT (RORγT)[46,40]. Rejection mediated by 
IL-17 is likely to be through the ability of this cytokine to rapidly recruit myeloid 
cells [47].  
Tregs produce IL-10 and TGF-β and they express Forkhead box P3 (FOXP3) 
[48]. Tregs have the capacity to suppress exacerbated immune responses and 
maintain tolerance in autoimmune diseases and transplantation [49,50]. In 
addition, through cell-contact Tregs can dampen effector T cell responses [48]. 
However, Tregs can induce Th17 T cell differentiation and augment IL-17 
production and can be themselves converted into Th17 T cells [51]. 
B) CD8 T cells 	  
CD8+ T cells, once activated in an antigen specific manner, can damage the 
graft via one of two pathways: granule exocytosis, or the Fas pathway [46].   
C) B cells 	  
Initially Szenbreg and Warner suggested that B cells were neither necessary 
nor sufficient for immune responses against an allograft [52]. They compared 
skin graft rejection in two groups of chickens. The first group was 
thymectomized, while the second group had their bursa of fabricius (B cell 
source) removed. The thymectomized group in this experiment accepted the 
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graft fully and permanently, while the B cell deficient group rejected the graft at 
the same time as the control [52]. These results suggested that rejecting a 
transplant was a process associated with the thymus, not the bursa of fabricius 
[52,53]. However, subsequent studies in this area have shown that B cells play 
a key role in the immune response to organ transplantation both in terms of 
rejection and tolerance, Zarkhin et al. showed that B cells amplify T cell 
responses during graft rejection [54]. In this study, they found that CD20+ B 
cells in the graft are highly activated and express high levels of MHC II, 
supporting their hypothesis that B cells exacerbate anti-graft responses [54]. 
The presence of activated B cells in the graft was associated with reduced graft 
survival and a resistance to immunosuppressive agents [54]. Recently, the role 
of B cells was studied in chronic renal rejection, acute cardiac rejection, and 
skin rejection by depleting B cells from mouse transplant recipients using CD20 
and CD19 depleting mAbs (CD20 mAb depletes mature B cells, while CD19 
mAb deplete mature B cells, plasmablasts, and some plasma cells) [320]. 
Although depleting B cells has stopped the development of specific allo-IgG, it 
did not influence the rejection process of cardiac allografts [320]. In renal 
rejection, CD19 mAb treatment, but not CD20 mAb, significantly decreased the 
rejection and prevented allo-specific-IgG development [320]. However, 
depleting B cells in skin model accelerated the skin allograft rejection [320]. 
These results indicate that B cells can both up-regulate and down-regulate allo-
immune responses depending on the intensity of the allo-responses and the 
organ transplanted [320]. 
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In animal models, AbuAttieh et al. found that B cell deficient JH-/- mice rejected 
fully miss-matched skin graft at the same time as the controls [57]. On the other 
hand, it was shown by Waswska et al, in a cardiac transplant model, that only 
85% of µMT mice rejected their grafts after 14 days, while 100% of WT mice 
rejected theirs [58]. In addition, they found that cardiac allograft rejection in 
µMT mice could be restored through donor-specific antibody administration 
[58]. The differences in the results obtained by the two groups might be due to 
the fact that µMT mice retain some B cells and antibody, while JH-/- mice 
completely lack B cells and antibodies [57].  
In humans, depleting B cells by using anti-human CD20 mAbs has improved 
graft survival in some studies [59]. However, the mechanism by which depleting 
B cells impacts graft survival is not clearly understood. It could be a result of 
the inhibition of B cell antibody-dependent or antibody-independent responses. 
Some studies however suggest that depleting B cells is not beneficial to graft 
survival. For instance, Clatworthy et al. found that cellular rejection in kidney 
transplant was observed in 83% of anti-CD20 mAb treated transplant 
recipients, while it was only observed in 14% of anti-CD25 treated patients, 
indicating that B cells might regulate the immune system [60]. They found 
elevated serum concentrations of IL-10, IL-6 and TNF-α in the grafts of patients 
who had received anti-CD20 mAb compared to controls [60]. Clatworthy and 
colleagues suggested that the absence of B cells resulted in an increase in pro-
inflammatory cytokines and activated antigen presenting cells and T cells [60]. 
The role of regulatory B cells has not been fully described in transplantation; 
however, it has been explored in autoimmune models and will be describe 
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latter. Altogether the results of Clatworthy et al. suggest that depleting B cells 
could lead to the depletion of regulatory B cell subsets and the deterioration of 
the graft [61].  
A recent study by Newell et al. analyzed gene expression by peripheral blood 
lymphocytes isolated from immunosuppressant free spontaneously tolerant 
kidney transplant recipients and compared them to transplant recipients 
receiving immunosuppressive agents with stable renal graft function [55]. The 
group of tolerant recipients who were not receiving immunosuppressive drugs 
expressed higher levels of mRNA for IGKV4-1, IGLL21 and IGKV1D-13 [55]. 
These genes encode the variable region segments of Ig light chains [55]. 
Therefore, Newell and colleagues called it a “B-cell signature” and suggested 
that these genes could help in distinguishing those kidney transplant recipients 
who need immunosuppressive agents from those who do not [55, 56].  
These mixed results from the literature suggest that B cells can exhibit both 
pathogenic as well as protective roles in transplantation, but this answer is not 
completely clear yet [66]. 
Antibody 	  
Antibody can be involved in the three types of rejection: hyper-acute, acute and 
chronic rejection [63]. Antibodies mediate rejection by two mechanisms: 
complement-dependent and complement-independent pathways [63]. In the 
complement dependent pathway, the classical complement pathway is 
activated resulting in membrane attack complex formation that leads to cellular 
injury [63]. For example, C1q binds to IgM and IgG that have attached to 
alloantigen on the allograft epithelium, and this initiates the classical 
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complement pathway [63]. Moreover, the complement products (C3a & C5a) 
act as chemo-attractants for inflammatory cells whose infiltration results in 
inflammation [63]. In the complement independent pathway innate immune 
cells such as Natural Killer (NK) cells and macrophages are involved through 
their interaction with antibody bound to the allograft via their cell surface Fc 
receptors [63]. These interactions will lead to antibody dependent cell 
cytotoxicity (ADCC) [63]. 
1.1.4 Transplant tolerance 	  
Tolerance is the state defined as the acceptance of the allograft by the recipient 
without the need for immunosuppressive drugs [2]. Although globally 
immunosuppressive treatments help to increase the degree of success of 
transplantation they can have many side effects such as infections and 
malignancies [64]. As a result, attempts have been made to replace the use of 
globally immunosuppressive drugs with more targeted therapies. One example 
is the use of Rituximab for B cell depletion. Rituximab is a humanized anti-CD20 
antibody that depletes B cells [65]. However, as mentioned earlier, the depletion 
of B cells has provided mixed results, suggesting that B cells can play both 
pathogenic as well as protective role in transplantation [66]. Another approach 
for the induction of tolerance to allografts has been to achieve mixed 
hematopoietic chimerism [1]. This constitutes the depletion of the hematopoietic 
system and its reconstitution with syngeneic as well as allogeneic bone marrow 
[1]. This procedure however is associated with unpleasant side effects [1]. 
Other approaches for the induction of transplant tolerance include the use of 
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antibody-mediated blockade of co-stimulatory molecules, or adoptive cell 
therapy with ex vivo expanded Tregs or DCs [1].  
One of the barriers to tolerance induction that face scientists is the presence of 
memory T and B cells [1,2]. Memory T cells respond faster than naïve T cells to 
antigens with little or no requirement for high antigen dose or co-stimulation, 
and for that reason memory T cells are considered one of the greatest 
challenges to the induction of tolerance [1,2]. Memory T cells that are specific 
for alloantigens can be generated in three different ways [1,2]. One-way is 
through pre-exposure to antigens via previous transplantation, pregnancy or 
prior blood transfusion [1,2]. Secondly, T cells can cross-react with and 
recognize more than one antigen [1,2]. This cross reactivity might be one of the 
reasons behind the complexity of generating tolerance in primates and humans, 
making it necessary to keep animals in pathogen free housing to study 
transplant immunology [2,67]. Finally, memory T cells can be generated as the 
result of homeostatic proliferation in which T cells under self antigen-MHC 
complex; cytokines and chemokines expand in a lymphopenic environment 
[1,2]. Memory B cells, exist as a result of previous sensitization [1,2], and get 
rapidly activated in response to their re-exposure to immunizing antigen 
[68,69,70]. Moreover, they require less help from T cells and lower antigen dose 
than naïve B cells [71]. Memory B cells are associated with complement fixation 
through IgG causing hyper-acute rejection [1]. 
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1.1.5 The role of Major Histocompatibility Complex 
(MHC) molecules 	  
The main cause of allograft rejection is the capacity of T cells to recognize 
alloantigen, which is mainly encoded within the MHC genes [1]. MHC genes in 
humans are known as human leukocyte antigens (HLA), and they are divide 
into MHC I and MHC II genes [64]. HLA-A, HLA-B and HLA-C are the three 
genes that encode MHC I molecules, while MHC II genes are composed of 
HLA-DQ, HLA-DP and HLA-DR [64]. In mice, MHC molecules are encoded by 
the H-2 region, which includes class I and class II molecules [64]. Class I 
includes three encoding genes K, D and L, and for class II the encoding genes 
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1.2 B cells 
1.2.1 B cells development 	  
In general, B cells are divided into two distinct populations: B-1 and B-2 B cells. 
MZ and FO B cells represent the mature B2 populations [72]. B1 B cells can be 
subdivided into B1a and B1b B cells according to their CD5 expression (B1a 
are CD5+ while B1b are CD5-) [72]. B1 B cells are mainly found in the peritoneal 
and pleural cavities, and produce natural antibodies, in particular IgM and IgA 
[72]. Natural antibodies are polyreactive antibodies with low affinities that have 
specificities for a wide variety of antigens such as lipids, nucleotides and 
polysaccharides [73,74,75]. Unlike B2 B cells, B1 B cells are activated via IL-5, 
IL-10, TLRs or whole bacteria, and not via their BCR [76,77]. Activated B1 cells 
migrate into the omentum, spleen, regional lymph nodes or intestinal	   lamina 
propria [76,78]. Subsequently, activated B1 cells differentiate and produce 
natural IgM and IgA [76,78]. Therefore, B1 cells are innate-like B cells [79]. 
Although it is still unclear how B1 cells develop, two hypotheses have been 
proposed [80,81]. First of all, the “lineage hypothesis” which suggests that B1 
and B2 arise from different B cells precursors [80,81]. Secondly, the “induced 
differentiation hypothesis” which suggests that B1 and B2 B cells develop from 
a common precursor; depending on the specific signals that the precursor 
receives during maturation and selection cells either differentiate into B1 or B2 
B cells [80,81]. 
B2 cells develop throughout adult life in the bone marrow (BM) [3,82]. The 
medullary cavities in bone are occupied by a soft tissue known as the BM, 
which is surrounded by an outer structure called endosteum that is lined by 
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variety of cells such as stromal reticular cells [3,82]. The latter cells are also 
found close to the central sinus, where they are called adventitial reticular cells 
[3]. The BM is rich with medullary vascular sinuses that drain into the central 
sinus where blood is collected and exits the BM [83]. The adventitial reticular 
cells serve as a gateway for B cells to enter the central sinus, and the 
circulation [3].  
Prior to the release of B cells into the circulation, a process of selection and 
programmed cell death take place. Stromal reticular cells play a key role in the 
development of B cells and survival [3]. B cells progenitors interact with stromal 
reticular cells, and are promoted to proliferate and mature [3]. The binding of B 
cells progenitors and early pre-B cells to stromal cells is mediated through the 
interaction between VCAM-1 on stromal cells and integrin VLA-4 on developing 
B cells, also it involves the interaction between other cell adhesion molecules 
[98]. CD117 on pro-B cells binds to SCF (stem-cell factor) expressed on the 
surface of the stromal cells, this interaction induces B cell progenitor 
proliferation via the activation of kinase (phosphatidylinositol (PI)–3 
kinase/protein kinase (PI-3 kinase)) [98]. IL-7 is produced by stromal cells and it 
is required at early stages of B cell development where it is essential for cell 
proliferation and development [98]. The stromal cells also continuously produce 
the chemokine CXCL12 (stromal cell-derived factor 1, SDF-1) that retains the 
cells in the stroma during their development in the BM [98].  
At the earliest stage of B cells maturation upon their interaction with stromal 
cells, B cells are known as pro-B cells [98]. At this stage, immunoglobulin (Ig) 
heavy chain locus rearrangement occurs. Immunoglobulins are composed of 
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heavy and light chains and both contain variable (V) and constant (C) regions 
[98]. The V domain of the light chain is encoded by two DNA segments the VL 
gene segment and the JL (Joining) gene segment, whereas the heavy chain, the 
V region is encoded by VH and JH gene segments together with a third segment 
known as diversity or DH gene segment [98]. The C region is encoded in 
different segments and joins the V domain at the end by RNA splicing [98]. As 
mentioned above, Ig heavy chain locus rearrangement takes place first, in 
which DH join JH segment (early pro-B cell) then DJH joins VH (late pro-B cell) 
[98]. Subsequently, the µ heavy chain (part of IgM) is expressed intracellularly 
as a result of VDJH productive joining, this stage known as late pro-B cell stage 
[98]. At this stage, the µ chain combines with a surrogate light chain. The joining 
of µ chain to the surrogate light chain leads to the expression of the pre-B cell 
receptor on the cell surface that provide signals essential to stop VDJH 
rearrangement and to promote cell division into small pre-B cells [98]. Here, 
light chain rearrangements begin.  
The light chain has two types: Lambda (λ) and Kappa (κ). Immunoglobulin 
consists of either κ or λ never both, however no functional differences have 
been found between them [98]. The light chain rearrangement involves the 
joining of VL to JL [98]. In general, κ chain locus rearrangement occurs before λ; 
when κ rearrangement fails λ rearrangement takes place, and when λ 
rearrangement fails the cell die [98].  Pre-B cells that express self-reactive 
immunoglobulin or have rearranged non-productive receptor genes undergo 
apoptosis and are phagocytosed by BM resident macrophages [3]. Surviving 
cells differentiate further into immature B cells before they leave the BM and 
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interact with adventitial reticular cells that facilitate their exit into the circulation 
as transitional-1 (T1) B cells (a transient transitional B cells stage), which 
express IgM, low levels of CD21, but not IgD or CD23 [3,84]. Immature B cells 
undergo a process of receptor editing and programmed death (negative 
selection) [98]. Immature B cells that recognize self-antigens in the BM are 
retained and can rearrange a new light chain that combine, a process called 
receptor editing [98]. However, those cells that form new receptor that again 
recognizes self-antigen undergo programmed death [98]. Successful receptor 
editing, in which the new receptor is not reactive, leads to survival [98]. 
T1 B cells have the potential to recirculate between the BM and the spleen [84]. 
In the splenic follicles T1 B cells mature into transitional-2 (T2) B cells that 
express IgD and CD23 [84]. At this stage, T2 differentiate into either follicular 
(FO) B cells or into marginal zone precursor (MZP) B cells that in turn mature 
into marginal zone (MZ) B cells [84]. The transitional stage of B cell 
development has also been suggested to contain an additional transitional 
group termed transitional-3 (T3) [85]. T3 cells were proposed by Allman et al. 
who suggested that T3 give arise to FO B cells without the proliferative burst 
previously ascribed to T2 cells, which give arise to both FO and MZ B cells [85]. 
However, this hypothesis has been challenged and it has been suggested that 
the T3 population comprises anergic B cells rather than the progenitors of FO B 
cells [86]. Moreover, Pillai et al. have suggested that T2 exist in two 
populations: T2 Follicular progenitors (T2-FP) and T2 Marginal Zone progenitor 
(T2-MZP) [87,88]. T2-FPs have been suggested to be present in all secondary 
lymphoid organs and differentiate into FO B cells [85,89], whereas T2-MZPs are 
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restricted to the spleen and differentiate into MZ B cells [89,90]. Whether T2 B 
cells differentiate into FO (IgD+, IgM+, CD23+ and CD21mid) or MZP and MZ B 
cells depends on several factors such as the strength of BCR (B cell antigen 
receptor) signals; it also requires NOTCH 2 and canonical Nuclear Factor-κB 
(NF-κB) activity [84].  
MZP B cells express CD23, CD1d, CD21, IgM and IgD and mature into MZ B 
cells that express IgD, IgM, CD1d and CD21, but are CD23- [84]. MZ B cells are 
located between the marginal sinus and the red pulp [84]. As mentioned earlier, 
MZ B cells express high levels of CD1d and CD21 [84]. CD1d expression by MZ 
B cells facilitates lipid and glycolipid presentation to invariant natural killer T 
(iNKT) cells, while the expression of CD21 allows MZ B cells to transport 
circulating immune complexes to the follicles in the spleen and deposit them 
with follicular dendritic cells [91,92,93,94]. MZ B cells share some features with 
memory B cells such as the ability to self-renew, a long-life span and a pre-
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1.2.2 Germinal Centre formation 	  
Following exposure to microbial antigens B cells become activated by the 
internalization of small soluble antigens that gain access to the follicle via 
specialized transport system; these antigens are recognized by the B cell 
surface IgM and IgD receptors [99,100,101,102]. However, B cells require 
antigen sampling macrophages and DCs (located in the marginal zone area 
(spleen) or paraconrtical area (lymph nodes)) to present large antigens 
[99,100,101,102]. Following this activation of B cells through their surface Ig 
receptors they migrate to the T-B border area (the border between T zone and 
follicle) [103]. At T-B border, B cells meet and make cognate interactions with 
specialized CD4+ T cells, known as T follicular helper (TFH) cells 
[104,105,106,107,108]. The TFH cells are generated following the activation of 
CD4+ T cells by IL-12 and via MHC II expressed by activated DCs that have 
migrated from the invasion site to T cell zone [103,109]. Here, the initial 
activation of B cells through IL-4, IL-21 and IFN-γ produced by TFH cells and 
their interaction with CD40L on TFH cells, initiates the development of antibody-
secreting cells (ASC) [103,110]. ASC develop extra-follicularly, and produce a 
fast antibody response to antigen, either in response to T cell independent type 
2 (T1-2) antigens, which are large antigens that express epitopes in highly 
repetitive manner and they can activate B cells directly via their BCR without 
the need of co-stimulatory signals [111] (in case of MZ & B1 B cells [112]), or in 
a T cell dependent manner [113]. Extra-follicular ASC undergo apoptosis 
around a week after infection/immunization, and they mainly produce non-
somatically mutated IgM [113].  
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Both MZ and FO B cells can form extra-follicular ASCs, however, after a week 
activated FO B cells start developing a Germinal Centre (GC) in the follicle [3]. 
Rapid proliferation of the activated FO B cells excludes the non-activated IgM+ 
and IgD+ B cells to the surroundings of the GC to form a structure known as the 
mantle zone [3]. The follicle at this point is known as the secondary follicle [3]. 
The secondary follicles consist of a dark zone, where B cells undergo clonal 
expansion and somatic hyper-mutation, and a light zone, where B cells 
selection and class switching occurs [3].  
Clonally expanded B cells are known as centroblasts that subsequently 
undergo somatic hyper-mutation [3]. The latter is a process in which the 
variable region of the rearranged Ig gene is modified in order to generate a 
BCR with a greater affinity for the targeted antigen [110,114,3]. Modified 
centroblasts are termed centrocytes, which enter the light zone and undergo 
selection by the follicular DCs [3]. Only B cells with high affinity get to survive 
and interact with TFH cells in the follicles where they may class switch their Ig 
heavy chain constant region gene from IgM and IgD to other classes of Ig 
[3,103]. B cells that fail to pass the selection process apoptose and are 
phagocytosed by follicular macrophages [3]. Class switched B cells 
subsequently differentiate either into plasma or memory B cells [3,103,114]. 
The GC diminishes after this stage [114].  
Signals involved in the commitment decision of B cells to become plasma or 
memory B cells are not fully known [115,116,117]. However, several 
transcription factors have been identified to be involved in this decision, for 
example, paired box protein 5 (PAXS) is important for memory B cell 
	   32	  
differentiation, while the repression of PAXS together with the expression of X-
box-binding protein 1 (XBPI) is crucial for plasma cells commitment 
[115,116,117]. In mice, GC B cells are characterized by the high expression of 
GL7 (T and B Cell Activation Marker) and CD95 and they are CD38-, whereas 
plasma and memory B cells are negative for both markers (GL7 & CD95) [118]. 
However, plasma cells express high levels of CD138, and memory B cells are 
CD138-, CD95- and CD38+ [118].  Memory B cells generate IgG expressing 
extra-follicular areas as well as IgM memory B cell follicles in the lymph nodes 
[119]. Upon secondary antigen exposure, IgM memory B cells induce a 
secondary germinal centre reaction, while IgG memory B cells rapidly 
differentiate into plasmablasts [119,120]. Memory B cell expansion and 
differentiation is controlled by their interaction with antigen specific memory TFH 
cells residing in the draining lymph nodes to induce their responses upon 
antigenic re-challenging. In addition non-specific stimulation of memory B cells 
through their TLRs appears to be important for the expansion of polyclonal 
memory B cells [103,321,121]. Although the memory B cell responses induced 
by TFH cells in draining lymph nodes occur more rapidly than memory B cells 
responses induced in memory secondary lymphoid organs devoid of TFH cells, 
these responses are still kinetically slow, and the generation of faster responses 
requires their interaction with innate cells such as invariant NKT (iNKT) cells, 
DCs, macrophages and other cells [103,321]. In fact, B cells produce early 
waves of IgM and IgG when they interact with TFH cells in the presence of the 
innate immune cells [103].  On the other hand, plasma cells migrate to the BM, 
and continuously produce antibodies [122,123,124]. 
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1.2.3 B cell functions 	  
In addition to the role of B cells in the humoral arm of the immune system, 
where they produce antibodies for opsonization and complement activation, 
initiate cellular cytotoxicity, form immune complexes and facilitate endocytosis, 
they also participate in shaping the immune system responses in a variety of 
antibody-independent ways [125]. For example, B cells can be very potent 
antigen presenting cells (APC) that capture specific antigen via their BCRs and 
present antigenic peptides in an antigen specific manner via their MHC class I 
and MHC class II to both CD8 and CD4 T cells respectively [126,127,128]. 
Activated B cells internalize antigens through their BCR, process and present it 
by MHC class I and MHC class II [125,126]. In order for B cells to function as 
APCs they need to receive two signals, the first upon encountering their specific 
antigen (BCR signal), and the second through their interaction with CD40L on 
activated CD4+ T cells [133]. B cells can function as APCs for CD4 T cells 
without the CD4 T cells having been pre-activated by other APCs such as DCs 
[133]. Here, B cells internalize and process antigens and present them on MHC 
II that interact with TCRs expressed on CD4 T cells, and express CD86 
molecules that cross-link with CD28 on CD4 T cells [129,130,131,132]. These 
two signals are sufficient for the expression of CD40L on CD4 T cells that then 
interacts with CD40 on B cells. Following CD40-CD40L interaction CD86 
expression is maintained and CD80 and MHC II are up regulated, and provide 
full activation for both T and B cells [129,130,131,132,133]. 
As well as the ability of B cells to provide signals to T cells in an antigen-
dependent manner, they deliver essential signals for the activation and 
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proliferation of both naïve and memory CD4 T cells through CD80 and CD86 
[134,135,136]. An experiment that was performed using mice that lacked the 
expression of CD80 and CD86 on their B cells demonstrated that the 
expression of CD80 and CD86 by B cells was needed for auto-reactive T cell 
proliferation and activation in a model of arthritis (proteoglycan (PG)-induced 
arthritis) [136]. In vitro, challenging CD4 T cells obtained from arthritic mice 
whose B cells were CD80/CD86 deficient with PG (obtain from cartilage) 
resulted in less proliferation of CD4 T cells compared to the WT CD4 T cells 
[136].  
B cells produce a variety of pro-inflammatory cytokines such as IL-6, TNF-α, 
IFN-γ and IL-12 [125]. According to their cytokine profiles B cells have been 
divided into B effector 1 (“Be1”) and “Be2” cells [137,138,139]. The presence of 
antigen, Th1 T cells or/and TLRs signals as well as Th1 cytokines (IFN-γ and IL-
12) leads to the generation of Be1 B cells that secret IL-4, IL-13, IL-2, IL-10, IL-
6 and TNF-α [137,138]. On the other hand, Be2 cells produce IL-2, IL-4, IL-13, 
TNF-α, IL-6, IL-10 and small amount of IFN-γ and IL-12 in response to T cell 
priming, antigen and Th2 cytokines [137,139]. Together with the capacity of B 
cells to support T cell inflammatory immune responses they also can act as 
regulatory cells through several well-defined mechanisms including T cell 
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1.3 Regulatory B cells 	  
The history of regulatory B (Bregs) cells starts in the1970s, with the idea that B 
cells down-regulate the immune system through the production of “inhibitory” 
antibodies [143]. This study was later followed by a series of papers 
emphasizing that B cells have antibody-independent immunoregulatory function 
[144]. For instance, in 2002, Mizoguchi and colleagues found that IL-10 
producing CD1d high B cells have the capacity to down-regulate chronic colitis 
[145]. In 2007, regulatory B cells were phenotyped in more detail by Evans et 
al. in an arthritis model, where they described Bregs that express high levels of 
CD21, CD23 and IgM the characteristic markers for T2-MZP B cells [146]. 
However, various phenotypically distinct subsets of B cells with regulatory 
functions have been subsequently identified in models of inflammation and 
autoimmunity. Generally, these cells are characterized by IL-10 production. In 
this section I will discuss the different subsets of B cells that have been 
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1.3.1 Phenotypically distinct subsets of regulatory B 
cells 
 
The two most well defined subsets of B cells with regulatory function are the T2-
MZP B cells, which will be termed “Bregs”, and the B10 [144]. These two 
subsets share some common features such as CD19, CD21, CD24 and CD1d 
expression (Figure 1.1) as well as being mainly localized in the spleen, and they 
both produce IL-10 [144]. However, the signature of B10 B cells is their 
expression of CD5 that Bregs do not express, while Bregs express CD23 that is 
not found on B10 B cells (Figure 1.1) [144]. Also, Bregs suppressive capacity 
was initially linked to CD40 engagement, while B10 was associated with TLRs 
ligands (in particular LPS) [144].  
MZ B cells (CD21+, CD24+, CD23- and CD5-) have also been identified to be 
regulatory (Figure 1.1), however, the idea of MZ B cells being regulatory is 
controversial. In a contact hypersensitivity (CHS) model the adoptive transfer of 
MZ B cells down-regulate CHS responses in CD19-/- mice [147], whereas their 
adoptive transfer fails to protect from the disease in CIA (Collagen-induced 
arthritis) model [144]. Recently, an additional subset has been added to the list, 
the B killer cell, called killer because they induce the apoptosis of arthritogenic T 
cells in an arthritis model [144]. B killer cells induce apoptosis via expression of 
Fas ligand (Figure 1.1), and they share CD5 expression with B10 B cells [144]. 
Additionally, stimulating B cells with a GM-CSF and IL-15 ‘fusokine’ (GIFT15) 
induces a subset of regulatory B cells that express T2-MZP B cells markers as 
well as CD138 (a plasma cell marker). When adoptively transferred GIFT15 
induced Bregs can suppress experimental autoimmune encephalomyelitis 
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Figure	  1	  .1	  phenotypically	  distinct	  subsets	  of	  regulatory	  B	  cells. 
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A) T2-MZP B cells “Bregs” 	  
Bregs with a T2-MZP B cell phenotype have been reported in several 
autoimmune models such as CIA and a murine model of lupus [146,149]. In 
arthritis, the transfer of T2-MZP B cells isolated from naïve mice suppresses the 
development of CIA in DBA/1 mice [146]. Moreover, the transfer of T2-MZP B 
cells obtained from mice in the remission phase of arthritis has a more powerful 
regulatory effect [146]. Adoptive transfer of low numbers (4 x 105 cells) of T2-
MZP B cells from mice in remission from arthritis achieved a greater degree of 
suppression of arthritis than transfer of the same number of T2-MZP B cells 
from naïve mice [146]. 
The mechanism described to be associated with the suppressive capacity of 
T2-MZP B cells in the CIA model was the ability of T2-MZP B cells to produce 
IL-10 [146]. It was observed that the majority of IL-10 produced by splenic B 
cells isolated from mice in the remission phase of arthritis was by T2-MZP B 
cells following re-stimulation with collagen in vitro [146]. Moreover, the adoptive 
transfer of IL-10-/- T2-MZP B cells did not protect the mice form CIA [146].  
In MRL/lpr mouse model of lupus, the absolute number of T2-MZP B cells 
correlated with the severity of the disease, however, the adoptive transfer of T2-
MZP B cells failed to protect from the disease [149]. T2-MZP B cells, in this 
model regain their suppressive capacity after being activated in vitro with anti-
CD40 mAb, following which the transfer of these cells delayed the onset of 
lupus like disease and prolonged the survival of the mice [149].  
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B) Marginal Zone B cells 	  
MZ B cells produce IL-10 and some IL-6 in response to TLR-2 and 4 ligation, a 
feature that is amplified when they are co-stimulated via CD40 [150,151]. IL-10 
producing MZ B cells were able to delay colitis in a Gαi2-/- mouse model mouse 
of colitis [152]. The transfer of T cells obtained from Gαi2-/- mice to syngeneic 
RAG2-/- mice induces colitis. However, transferring the T cells together with WT 
splenic MZ B cells induced temporary protection [152]. This protection was not 
however as efficient as that observed using mesenteric lymph node B cells 
which provided permanent protection from colitis [152]. Notably the purity of MZ 
B cells in these experiments were around 55%, suggesting that this 
suppression could be due to the presence of other B cell subsets, including T2-
MZP B cells [152]. In the CIA arthritis model, adoptive transfer of B cells that 
had been isolated from arthritic mice treated with apoptotic cells could protect 
mice from arthritis. IL-10 was shown to be necessary for this protective effect 
and, given that MZ B cells were the major IL-10 producers in vitro, it was 
suggested that MZ B cells were the regulatory subset [290]. However, Evans et 
al. demonstrated that the transfer of purified MZ B cells failed to protect from the 
disease in the CIA model [146]. Therefore, as mentioned earlier, MZ B cells 
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C) B10 	  
Tedder and colleagues were the first to identify B10 cells. In a contact 
hypersensitivity model (CHS) they found that CD19+ CD5+ CD1d+ IL-10 
producing B10 B cells were markedly increased in hCD19Tg mice (mice which 
overexpress CD19) [153]. These mice displayed reduced oxazalone mediated 
inflammation compared with WT mice [153]. In contrast, in CD19-/- mice the 
onset of inflammation was more severe compared to WT mice, however, the 
transfer of B10 B cells delayed the onset of disease via an IL-10 dependent 
mechanism [153]. In an EAE model, a Th1 dependent model of human multiple 
sclerosis, [154,155] the depletion of B cells using a CD20 mAb 7 days prior to 
EAE induction exacerbated the disease [154,155]. The disease was normalized 
upon the adoptive transfer of CD5+ CD1d+ B cells, but not other B cell subsets. 
The adoptive transfer of IL-10-/- B10 B cells did not delay EAE development, 
supporting the hypothesis that the suppressive capacity of B10 B cells is 
mediated via IL-10 [156]. The link between T2-MZP Bregs and B10 B cells is 
still under investigation [144]. However, it has been suggested that B10 and T2-
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D) FasL+ “Killer” B cells 	  
As discussed earlier “killer” B cells express Fas ligand, which induces the death 
of target cells through direct contact with Fas [144]. These B cells share CD5 
expression with B10 cells [144]. The expression of Fas ligand by B cells was 
first reported after activating human B cells with LPS or PMA/ionomycin [157], 
followed by a series of studies addressing the pathogenic affect of FasL 
expressing B cells on the progress of several malignant B cell diseases and 
during viral infection [158-164]. However, in a schistosoma infection model, 
CD5+ FasL+ B cells were found to be important in inducing the apoptosis of 
antigen-specific T cells [165]. Moreover, they can induce the apoptosis of 
arthritogenic T cells leading to the suppression of arthritis [165,166]. The 
tolerogenic properties of “Killer” B cells were also addressed in a transplant 
model (male to female skin graft) [167]. In this model, the adoptive transfer of 
WT splenic B cells was able to induce tolerance, whereas the transfer of FasL-/- 
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1.3.2 Regulatory B cell requirements and functions 	  
IL-10 producing B cells require signals through TLRs, CD40, CD80, CD86 and 
BCR to achieve their optimal suppressive capacity. Signals via TLRs have been 
reported to be required for B cell regulatory function, in particular for B10 B cell 
function, in which stimulating B10 with LPS (TLR-4) in vitro induced IL-10 
production that was essential for their suppression capacity [153]. Similarly 
providing B cells with strong stimulation through CD40 by using anti-CD40 mAb 
directs B cells to produce IL-10 as shown in several autoimmune models [168]. 
For instance, chimeric mice with CD40-/- B cells suffer from a more severe EAE 
than WT controls [168]. Furthermore, the adoptive transfer of in vitro anti-CD40 
mAb activated B cells suppresses the development of arthritis [169]. The 
importance of BCR signals for B cells with regulatory function is still under 
investigation. However, severe EAE developed in CD19-/- mice (CD19 is part of 
the BCR signaling complex) compared to WT mice, suggesting that the BCR 
may participate in the function of B cells with regulatory function. Nevertheless, 
this area requires more study [153,170,171].  
In addition, it has been documented that CD80 and CD86 are required for B 
cells to exert their regulatory function. In EAE, reconstitution of irradiated µMT 
mice with BM from B7-/- mice failed to protect mice from the disease after the 
adoptive transfer of encephalitogenic T cells. The mice in this experiment were 
protected only following reconstitution with BM from mice whose B cells 
expressed CD80 and CD86 [172]. 
The ability of B cells to exert suppression might require the combinations of all 
the stimuli mentioned above. The level of stimuli required by the B cells to 
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exhibit regulatory function and whether single or multi stimuli is required is a 
field that needs to be investigated. 
1.3.3 Regulatory B cells and transplantation 	  
There are as yet no mouse studies that link T2-MZP B cells or B10 B cells to 
the induction of transplant tolerance. A recent study, however, has identified 
TIM-1 (T cell Ig domain and mucin domain) as a marker for IL-10 producing B 
cells, and that TIM-1 plays an important functional role in IL-10 producing B 
cells [173]. Here, anti-TIM-1 was used to induce tolerance in an islet transplant 
model [173]. This was explained by an increase in TIM-1+ B cells expressing IL-
4 and IL-10 in anti-TIM-1 treated mice [173]. In contrast the treatment of B cell 
depleted mice with anti-TIM-1 accelerated islet allograft rejection [173]. Islet 
graft survival was enhanced by treating B cell depleted recipients with WT B 
cells together with anti-TIM-1 [173]. These results suggested that B cells play a 
role in TIM-1 induced tolerance [173]. It was also observed that anti-Tim-1 
induced tolerance is associated with Th2 shift, a decrease in IFN-γ with an 
increase in IL-4 and IL-10 expression [173]. Treating islet recipient B cell 
depleted mice with anti-TIM-1 increased IFN-γ expression, suggesting that B 
cells play a role in the Th2 shift observed in this model [173]. In addition, the 
adoptive transfer of TIM-1+ B cells, isolated from anti-TIM-1 treated recipient 
mice at day 14, to untreated islets recipient mice significantly prolonged the 
graft survival compared to adoptive transfer of TIM-1-/- B cells and to adoptive 
transfer of Tim-1+ B cells isolated from naïve mice [173]. These results again 
support the idea that B cells with regulatory function need to be activated in 
order to exert their suppressive function [173].  
	   45	  
1.4 Galectins 	  
Galectins are carbohydrate-binding proteins that contain conserved 
carbohydrate recognition domains (CRD) [174]. CRD are used to classify 
galectins, and they are responsible for carbohydrate binding [175]. In mammals 
galectins are divided into three groups according to their CRD [176,177]. The 
protypical galectin group consists of one CRD and can form dimers [175]. One 
group that contain galectin-3 only because of their unique structure (chimegic 
galectins), and the tandem repeat group, which contain at least two CRD linked 
through small peptide (Figure 1.2) [175]. Saccharides and galactose can bind to 
galectin carbohydrate binding sites, and different galectins can accommodate 
saccharides bound to galactose differently [178,179]. Therefore, each galectin 
is specific for different carbohydrate oligosaccharides [178,179]. Galectins can 
be found both extracellularly and intracellularly [174]. Extracellularly, galectins 
are secreted from cells via non-classical secretory pathways. Unlike classical 
pathways in which the secreted proteins contain an N-terminus that is required 
to direct the development of the polypeptide and the ribosome of the 
endoplasmic reticulum (ER), the proteins secreted via the non-classical 
pathway such as Galectins do not contain the N-terminus and do not get 
secreted from the ER [180,181,322]. Galectins function as bridges linking cells 
to each other and cells to their extracellular matrixes [174]. Galectins can also 
cross-link cell surface glycoproteins, triggering cascades of signals that mediate 
apoptosis, mitosis and cell cycle progression [174]. On the intercellular level, 
galectins mainly interact with proteins, and are involved in essential cellular 
functions such as pre-mRNA splicing [182,183], cell growth, apoptosis and cell-
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cycle progression (Figure 1.2), however, exactly how galectins are involved in 
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1.4.1 Galectin-1 	  
Galectin-1 (Gal-1) belongs to the prototypical group of galectins that contain 
one CRD [175] and exist as monomers and non-covalent homodimers. Each 
form has functionally different biological activities [184,185]. Homodimer or 
dimer Gal-1 (dGal-1) can separate into monomers (mGal-1) at low 
concentrations. These monomers can still bind to carbohydrate moieties, but 
with lower affinities [186]. 
Gal-1 is expressed both inside and outside the cells. On the intracellular level, 
Gal-1 can be found in the nuclei, cytosols and on the intracellular side of cell 
membranes [187]. In addition, Gal-1 binds to proteins intracellularly, while it 
binds to carbohydrates extracellularly [187]. Many extracellular carbohydrate 
ligands of Gal-1 have been identified that participate in Gal-1 mediated bridging 
of cells to each other, or to the extracellular matrix [187]. For instance, integrins 
and GM1 gangliosides are two of the major extracellular ligands for Gal-1. As 
mentioned above, Gal-1 binds to proteins intracellularly. Those proteins that 
have been identified as intracellular Gal-1 ligands do not however share 
structural similarities nor domains nor motifs, and the site of their interaction 
with Gal-1 is yet to be identified [188,189]. One example of a Gal-1 intracellular 
binding proteins is Ras. H-Ras-GTP recruits Gal-1 to the cell membrane forming 
stable complex (Gal-HRas) that in turn binds to Raf-1 and can activate the ERK 
pathway [188,189]. 
Gal-1 is involved in several cellular functions such as cell growth and cell 
migration. Gal-1 can regulate cell growth in a dose dependent manner. A Gal-1 
low dose triggers cell mitosis, whereas a high dose inhibits proliferation 
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[190,191]. Gal-1 facilitates cell adhesion by bridging the cell surface integrins to 
their extracellular matrixes [192,193]. Gal-1 deficiency in glioma cells results in 
a decrease in their motility and adhesion [194,195]. In motility, increased 
expression of Gal-1 was associated with an increase in RhoA expression. RhoA 
is a protein involved in actin polymerization and depolymerization [194]. 
1.4.2 Gal-1 and T cells. 	  
It has been reported that Gal-1 plays a critical role in T cell function; for 
example, Gal-1 can induce Th2 responses [175,203], influence T cell viability 
[202], T cell development [200,201,202], and many other functions. Also, Gal-1 
has been identified as one of the functional markers for Tregs, as Gal-1 
expression is up regulated following Treg activation through their TCR receptor 
[196]. Moreover, they found that blocking Gal-1 with anti-Gal-1 mAbs inhibited 
the suppressive function of the Tregs in humans [196].  
In the context of T cell development cells undergo a process of positive and 
negative selection during their development in the thymus to ensure the 
generation of T cells with functional TCR [197]. The selection is based on the 
reactivity between T cells TCR and thymic APCs, which presents self-peptide 
(MHC) [198]. Gal-1 is expressed by splenic cells, lymph node and thymic APCs, 
as well as thymic endothelial cells [199,200,201]. It has been demonstrated that 
Gal-1 mediates the interaction between T cells and thymic endothelial cells 
[200,201], and induces apoptosis of CD8+ CD4+ and some CD4- CD8- 
thymocytes [200,201,202].  
In addition to the involvement of Gal-1 in T cell development, Gal-1 can play an 
immunoregulatory role by shifting the immune responses from Th1 and Th17 to 
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Th2 responses [175]. Toscano et al. reported that Th1 and Th17 T cells, but not 
Th2 T cells, express a set of glycans on their cell surface that trigger cell death 
signals upon binding to Gal-1 [203]. Also, it has been reported that Gal-1 
secreted by Th2 T cells induces selective apoptosis in Th1 T cells, whereas 
Gal-1 produced by Th1 T cells generates Th2 cytokine secretion [202]. 
Moreover, Gal-1 can induce IL-10 production in both CD4+ and CD8+ T cells 
[204].  
1.4.3 Gal-1 and B cells 	  
Different studies have shown that Gal-1 plays a key role in B cell function, in 
terms of their immunoglobulin production [205], development [206], and their 
influence on T cells [207].  
A master regulator called Blimp-1 (B lymphocyte-induced maturation Protein-1) 
regulates the differentiation of plasma cells [205]. The ectopic expression of 
Blimp-1 was found to be associated with up-regulation in Gal-1 in mature B 
cells. Also, it was shown that deleting prdm1 (the Blimp-1 gene) resulted in a 
severe diminishing in the secretion of IgM, the expression of CD138, and Gal-1 
secretion upon LPS stimulation in vitro [205].  These results suggest that 
plasma cell differentiation is associated with Gal-1 induction in a Blimp-1 
dependent manner [205]. Furthermore, B cells that express a mutant Gal-1 that 
is retained within the cells had defective Ig production compare to WT B cells, 
suggesting that extracellular Gal-1 promotes Ig production by B cells [205].  
In B cell development, Gal-1 is involved in anchoring the interaction between 
stromal cell integrins and the pre-BCR on B cells, providing survival signals 
during their development [208].  
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1.4.4 Gal-1 in autoimmunity 	  
The role of Gal-1 has been studied in several autoimmune models including 
EAE [209], arthritis [210] and colitis [213]. The treatment of EAE mice with Gal-1 
resulted in a delay in the development of the disease [209]. In arthritis, injecting 
DBA mice at day 1 following the induction of CIA with fibroblasts engineered 
(cells were transfected with mGal-1 DNA) to secrete Gal-1 abrogated the 
disease. In this study, they also found that the lymphocytes isolated from 
draining lymph nodes exhibited Th2 immune responses at the end of the 
treatment [210]. 
1.4.5 Gal-1 in transplantation 	  
Xu et al. demonstrated that Gal-1 treatment 7 days prior to renal transplant 
prolonged the graft survival. These results were associated with a reduction in 
serum IFN-γ and CD8+ T cells [211]. In addition, it has been reported that Gal-1 
treatment improved the rate of morbidity and mortality in a model of GvHD by 
reducing Th1 responses and increasing the numbers of Treg cells [212]. As 
Gal-1 has the potential to suppress allo-reactive T cell responses it is possible 
that Gal-1 could be used as immunosuppressive agent in transplantation [187].  
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1.5 Toll-like Receptors  	  
For pathogens to successfully invade our bodies they have to evade two lines 
of defence: the innate and adaptive immune systems [214]. Innate immunity 
represents the first line of defence and contributes to the priming of the adaptive 
immune response [214]. Pathogen components are sensed by pattern-
recognition receptors (PRRs) that are expressed on innate immune cells [214]. 
These molecules recognize pathogen associated molecular patterns (PAMP) 
[214]. PRRs can also recognise damage associated molecule patterns (DAMP), 
which are revealed following cell necrosis [215,216].  
TLRs are member of PRR family [217]. So far 10 TLRs have been identified in 
humans, while in mice 12 TLRs have been listed [217]. The engagement of 
TLRs activates several signaling pathways that lead to NF-κB (Nuclear Factor-
κB) and IRFs (Interferon-regulatory Factors) translocation, and the subsequent 
release of pro-inflammatory cytokines (associated with NF-κB) and type I 
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1.5.1 TLRs ligands and signaling 	  
TLRs recognize PAMPS on both extracellular and intracellular molecules. 
These include the components of bacterial cell membranes. For instance LPS, 
a component of the cell wall of gram-negative bacteria, is recognized by TLR-4, 
while peptidoglycan, lipoproteins and lipopeptide components of gram-positive 
bacteria are recognized by TLR-2, TLR-1 and TLR-6 respectively [218,219]. In 
addition, PAMPs could also be extracellular proteins such as flagelin (part of 
bacterial flagella) which is recognized by TLR-3 [220,221,222]. PAMPs can also 
be nucleic acids such as bacterial and viral DNA, which consist of unmethylated 
CPG motifs, and are recognized by TLR-9 [220,221,222]. Beside DNA, single 
stranded RNA (TLR-7 and TLR-8 ligands) and double stranded RNA (dsRNA) 
(TLR-3 ligands) contain PAMPs and are mostly derived from virally infected 
cells [220,221,222]. 
TLR ligation triggers several intracellular signaling pathways, in particular 
MyD88-dependent pathways. MyD88 is an adaptor molecule that connects the 
intracellular domain of TLRs with IRAK4 [223,224,225]. The binding between 
MyD88 and IRAK-4, results in IRAK-4 phosphorylation inducing the kinase 
activity in IRAK-1, and the subsequent phosphorylation of IRAK-1 N-terminus 
[226]. This process of phosphorylation results in TRAF-6 recruitment and 
binding [226]. Afterward, the IRAK-1-TRAF-6 complex disconnects from the 
receptor, and at the cell membrane they interact with TAK1, TAB1 and TAB2/3 
[226]. As a result, TAB2/TAB3 and TAK-1 are phosphorylated, and translocate 
to the cytoplasm all together with TRAF-6 [226]. In the cytoplasm, TAK-1 is 
phosphorylated and as a result the IKK (IκB kinase) complex becomes 
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phosphorylated followed by NF-κB translocation [226]. IKK is a complex 
consisting of three subunits two of which are catalytic (Ikkα and Ikkβ) and one 
of which is regulatory the Ikkγ (also known as NF-κB essential modulator, 
NEMO) [226]. Activated IKK phosphorylates IκBs (a NF-κB inhibitor) [226]. NF-
κB is consist of P65, P52 and P50 and consistently present in the cytoplasm in 
an inactive form in a complex with its inhibitor IκB [226]. The phosphorylation of 
IκB by activated IKK results in the polyubiquitylation and proteasome 
degradation of IκB [225] and the subsequent release and translocation of NF-
κB [226]. 
The phosphorylation of TAK-1 following TLR ligation also triggers the mitogen-
activated protein kinase (MAPK) pathways [226]. Three MAPK pathways have 
been identified: ERK (Extracellular-signal-regulated kinase) pathway, P38 
pathway and Jun N-terminal kinase (JNK) pathway [227]. In general, MAPK 
pathways can be activated either though TAK-1 or though GTPase-mediated 
pathways that include Rho, RAC, RAS and CDC42. The activation of these 
molecules leads to the phosphorylation of Mitogen activated protein kinase 
kinase kinases (MAPKKKs) molecules, such as RAF, TAK (TGF-β-activated 
kinase) and MEKK (MAPK/ERK kinase kinase) [228]. The phosphorylation of 
MAPKKKs leads to the phosphorylation of MAPK Kinases (MAPKK) and the 
subsequent phosphorylation of MAPK (P38, JNK, and ERK). Once MAPK is 
activated they can translocate into the nucleus [228]. NF-κB and MAPK 
translocation leads to the transcription of a variety of cytokines and to an up-
regulation in the expression of co-stimulatory molecules. 
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A) NF-κB function and disease 	  
NF-κB activation and the subsequent translocation induces the expression of 
pro-inflammatory cytokines, chemokines and an up-regulation of co-stimulatory 
molecule expression [229]. It has been reported that NF-κB can play a 
pathogenic role in inflammatory diseases such as arthritis. For example, in 
rheumatoid arthritis NK-κB is found to be overexpressed in the inflamed 
synovium [230]. Moreover, by bronchial biopsies, asthma patients showed a 
correlation between the levels of NF-κB activation and the expression of 
cytokines and adhesion molecules that are associated with the disease [231]. 
Also, Helicobacter Pylori associated gastritis was characterized by an increase 
in NF-κB activation in gastric epithelial cells [232].  
Collectively, these studies suggest that targeting NF-κB could have a beneficial 
effect on inflammatory disease. However, several studies have revealed that 
chronic inflammatory conditions can be initiated by inhibiting NF-κB, in 
particular at epithelial surfaces, where epithelial cells maintain the immune 
homeostasis through NF-κB activity [233]. Mice that have deficiencies of NEMA 
in intestinal epithelial cells (IEC) have severe chronic colitis associated with 
increased levels of pro-inflammatory mediators, immune cell infiltration, and 
epithelial ulceration [234]. Also, NEMAIEC-ko mice showed severe intestinal 
inflammation, however, the underlying mechanism in these studies still unclear 
[235]. NF-κB remains an attractive therapeutic target for inflammation, but only 
if its complex role is fully understood [236]. 
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B) MAPK function and disease 	  
On the other hand, different members of the MAPK family are associated with 
different immune cell functions. For example, ERK has been associated with 
cell proliferation, meiosis and stress responses [237]. However, P38 appears to 
be more involved in inflammation and apoptosis [237]. In RA, all MAPK 
members where found to be activated in the synovial tissue of RA patients, 
interestingly each member was activated in different location [238]. For 
example, activated P38 was found in the synovial microvessels and cells lining 
the synovial layer, while activated ERK was localized in mononuclear infiltrates 
and cells within the area around the lining of the synovial microvessels [238], 
suggesting that MAPK members may contribute differently in the disease 
pathogenesis [239]. Inhibiting ERK activation was associated with a reduction of 
inflammation in an ear oedema model and osteoarthritis model [240,241]. P38 
inhibition has been found to block TNF-α, IL-1 and IL-8 production by 
monocytes [242,243]. Therefore, blocking P38 activation was found to be 
associated with a reduction in the clinical severity of RA. Indeed, P38 inhibition 
is now at phase II trail for RA [239].  
C) The role of P38, ERK and NF-κB in IL-10 production. 	  
Activation of P38 and ERK pathways has been associated with not only the 
production of pro-inflammatory cytokines, but also with the production of anti-
inflammatory cytokines such as IL-10 [244]. In a study by Zhang et al. it was 
reported that P38 and ERK inhibition, by the chemical inhibitors SB203580 and 
U0126 respectively, suppressed IL-10 production. In contrast blocking NF-κB 
translocation using SN50 up-regulated IL-10 production in recombinant 
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hemagglutinin B activated macrophages [244]. These results suggest that P38 
and ERK play an important role in up-regulating IL-10 production, while NF-κB 
may play the opposing role [244]. Supporting this hypothesis Reissinger et al. 
reported that macrophages showed down-regulation in P38 and ERK in 
response to Bordetella type III secretion system (machinery that allow the 
bacteria to insert their proteins into the cell cytoplasm), and this was associated 
with a decrease in IL-10 and IL-6 production compared to controls [245]. 
Driessler et al. have documented that pre-treating U937 (a human monocyte 
line), or PBMCs, with IL-10 in the presence of TNF-α blocked nuclear 
translocation of P65 and induced nuclear accumulation of P50 [246]. Also, it 
has been reported that NF-κB dependent luciferase activated LPS RAW 264.7 
(murine macrophage-like cell line) was significantly inhibited in LPS-activated 
RAW 264.7 in the presence of IL-10 [247]. P38 has also been reported to up-
regulate NF-κB, in a study by Saccani et al. P38 was found to play a crucial role 
in inducing inflammation and regulating NF-κB recruitment in LPS stimulated 
DCs [247]. Collectively, these studies reveal that ERK activation is associated 
with IL-10 production, while NF-κB inhibition up-regulates IL-10 production. P38 
involvement in IL-10 expression is controversial as some studies suggest that 
P38 activation is associated with IL-10 down-regulation, whereas other studies 
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D) The role of P38, ERK and NF-κB in CD80 and CD86 expression. 	  
With regard to CD80 and CD86 expression, it has been reported that blocking 
P38 and NF-κB with SB203580 and BAY-117082 respectively, inhibited CD80 
and CD86 up regulation in OK-432 (a Streptococcal preparation) activated DCs, 
while blocking ERK with PD98059 was associated with CD80 and CD86 up 
regulation [249]. In agreement with this study, a study by Arrighi et al. showed 
that blocking P38 inhibited the high expression of CD80, CD86, CD40 and HLA-
DR that is induced in LPS and TNF-α activated immature DCs, while blocking 
ERK did not affect the expression of any of these molecules [250]. 
1.5.2 TLRs and B cells 	  
One of the unique characteristics of B cells is the dual expression of antigen-
specific B cells receptors (BCR) and TLRs that permit B cells to integrate 
danger and Ag-specific signals [251]. TLR signals in B cells can play an 
important role in modifying their response in terms of cytokine secretion, 
antibody production and antigen presentation [251]. B cells can respond in a T 
cell dependent or independent manner, FO B cells represents the arm of the T- 
dependent immune responses, while B-1 and MZ B cells are the main players 
in T cells independent responses [251]. Therefore, MZ and B-1 B cells can be 
viewed as innate like cells that rapidly produce antibodies in response to 
pathogens without T cell help [251]. 
TLRs ligation induces rapid proliferation and antibody production, in particular 
the production of IgA (B-1 cells) and IgM (MZ B cells) [252,253,254], in a T-
independent fashion. MZ and B-1 B cells have a functionally stronger response 
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than FO B cells to TLR engagement; MZ and B-1 B cells express higher levels 
of co-stimulatory molecules and produce higher levels of IL-10 than FO B cells 
in response to TLR ligation [253,254,255,256]. Moreover, following TLR ligation 
MZ B cells are more efficient antigen presenting cells than FO B cells 
[253,254,255,256]. In addition, TLRs can regulate MZ and B-1 B cell 
localization and migration [257]. MZ B cells, for instance, express sphingosine-1 
phosphate receptor 1 (S1PR1) that retains the MZ B cells in the MZ [257]. 
Administration of a TLR-4 ligand (LPS) in vivo leads to MZ B cells migration into 
the follicles through S1PR1 down regulation [258]. Similarly B-1 B cells, which 
express high levels of integrins, down regulate their integrin and CD9 
expression following TLR ligation leading to their migration from the peritoneal 
cavity to site the of invasion to initiate fast and local antibody responses [259].  
Although TLR ligation is of greater importance to B cells involved in T-
independent responses, T dependent B cells responses can also be influenced 
by TLR ligation [252,253,260,261]. Activated FO B cells form germinal centers 
where they differentiate into either plasma or memory B cells [251]. GC B cells 
have been found to be more responsive to TLR ligation and express higher 
levels of MyD88 mRNA than FO B cells, suggesting that GC B cells are more 
sensitive to TLRs engagement [262]. Also, TLRs have been suggested to play a 
role in plasma cell differentiation [251]. 
TLR mediated cytokine secretion by B cells can alter CD4+ T cell polarization. 
Recently, Miles et al. found that apoptotic cells (AC), which express chromatin 
complexes and stimulate TLR-9, when adoptively transferred protected the 
mice from arthritis, unlike the transfer of ACs treated with DNase, which 
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removes TLR-9 ligand, that did not confer protection [264].  In addition TLR-9-/- 
mice were not protected from EAE upon AC-administration, suggesting a role 
for TLR-9 in mediating protection from disease [264]. Moreover, protection from 
EAE by AC treatment was restored by the adoptive transfer of WT but not TLR-
9-/- B cells together with AC, suggesting that TLR-9 is essential for B cells to 
maintain self-tolerance in heath [264]. 
1.5.3 The interaction of Gal-1 with intracellular 
signalling molecules 	  
The role of Gal-1 in TLR function or signaling has not received much attention. 
A study by Fuerter et al. investigated the intracellular pathways that lead to Gal-
1 expression following T cell activation [265]. T cell activation via TCR/CD3 
signals involves Lck and Fyn tyrosine kinase to initiate the pathway; blocking 
them with PP1 (Src family kinase inhibitor) inhibited Gal-1 expression in 
activated T cells, suggesting that Lck and Fyn activation are important for Gal-1 
activation and expression [265]. This study also investigated the down stream 
events of Lck and Fyn, which include ERK and P38 phosphorylation, and found 
that by blocking them lymphoproliferative responses and Gal-1 expression were 
inhibited [265]. These results suggest that Gal-1 expression by activated T cells 
requires ERK and P38 [265].  
It has recently been reported that blocking NF-κB, but not P38 or ERK, down-
regulated Gal-1 expression particularly in Th1 cells [266]. This study also 
reported that exogenous Gal-1 has an inhibitory effect on NF-κB activation 
[266]. Thus Gal-1 expression is regulated by NF-κB activity, and the expression 
of Gal-1 can lead to the inhibition of NF-κB [266]. It has been documented that 
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Gal-1 can interact with Ras at the cell membrane and activate the ERK pathway 
[187]. These studies indicate that Gal-1 interacts with a number of molecules 
that are involved in TLRs signaling pathways. These studies have so far all 
been carried out in T cells and the role of Gal-1 in B cell signaling pathways is 
as yet not well defined. 
1.5.4 TLRs and transplantation 	  
As mentioned earlier, transplant surgical process is associated with ischemia-
reperfusion injury that leads to the release of DAMPs [267,268]. The release of 
DAMPs activates and recruits the innate immune cells through their TLRs 
[267,269]. Briefly, released DAMPs activate donor or recipients APCs via their 
TLRs [268]. Activated APCs amplify the allo-responses through the production 
of cytokines, chemokines and growth factors that recruit neutrophils and 
activate monocytes to infiltrate the graft [268]. In addition, APCs up-regulate the 
expression of their surface co-stimulatory molecules and activate the adaptive 
immune cells [268]. All together they induce both tissue injury and the release 
of more DAMPs that might promote chronic rejection via the activation of cells 
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1.6 The Hygiene Hypothesis 	  
The hygiene hypothesis is the theory that there is a link between the increase in 
the rate of allergies and autoimmune diseases and the decrease in exposure to 
infectious agents, parasites and symbiotic microorganisms, such as an 
alteration in gut microbiota during child hood, which in turn leads to an altered 
development of the immune system [219]. This hypothesis has re-shaped our 
understanding of the role of microbes in normal immune function, suggesting 
that microbes can be beneficial for health and immune function [220]. Several 
studies have reported that commensal microbiota, in particular some gut 
microbiota, may influence the development of immune responses and protect 
from diseases [221,222]. A study by Shimomura et al. reported the influence of 
housing mice in CV and SPF facilities on the regulatory function exerted by B-1 
B cells in chronic colitis [274]. They found that maintaining TCR-α-/- mice, in 
which chronic colitis is mediated by IL-4 producing Th2 T cells, in CV facilities 
suppressed colitis, and that B cells in TCR-α-/- mice were more activated under 
CV environment compared to B cells obtained from mice in SPF facilities [274]. 
Moreover, they found that the adoptive transfer of B-1 B cells isolated from mice 
kept in the SPF facility into double knocked out mice (B cells-/- and TCR-α-/-) 
housed in the CV facility significantly suppressed the disease compared to the 
control, which received PBS [274]. These data suggest that the protection 
observed from Th2-mediated colitis by housing the mice under non-hygienic 
conditions is mainly due to the regulatory role that B-1 B cells play under the 
response to microbial flora [274]. Recently, in an allergic model, it has been 
demonstrated that treating mice with antibiotics affected their immune make up, 
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with higher concentrations in serum IgE and circulating basophil (mediators of 
allergy) [220]. Moreover, allergic responses were more severe in mice treated 
with antibiotics and exposed to dust allergen [220]. In this study, they also 
investigated the link between high levels of circulating basophils and serum IgE 
by testing the level of circulating basophil in RAG1 (B cell deficient) mice and 
mice where IgE was neutralized; they found no increase in the level of 
basophils suggesting a link between B cells [220]. Also, they have found that 
the commensal microbiota influence on B cells to produce IgE is MyD88 
dependent, where MyD88-/- mice (without antibiotic treatment) showed the 
same high levels in IgE and basophil observed in germ free and antibiotics 
treated mice, which also was seen in B cells MyD88-/- mice [220]. However, how 






	   65	  









 	  	  
	   66	  
2.1 Materials 
2.1.1 Antibodies & Reagents 	  
Table	  1	  
Extracellular surface Antigens Anti-mouse Antibodies 
Antibody 
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Extracellular surface Antigens Anti-mouse Antibodies 
Antibody 
To 
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Extracellular surface Antigens Anti-mouse Antibodies 
Antibody 
To 
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Table	  2	  
Intracellular Antigens Anti-mouse Antibodies 
Antibody 
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Table	  3	  
Cell culture antibodies 
Antibody 
To Conjugate Clone Isotype 
Manufacturer 
& Concentration (µg/ml) 
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Table	  4	  
Fluorescent in-situ hybridization (FISH-Flow) Probs 
Probe Targeted Position Sequence frm 5’ to 3’ end OPD code 
NON 
338 
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2.1.2 Anti-CD40 (FGK45 Hyridoma) culture and 
purification 	  
1x107 cells/ml of FGK45 hybridomas were kept in heat inactivated FCS (Foetal 
Calf Serum, Sera Laboratories International Ltd) and 10% DMSO 
(Dimethylsulfoxide, Sigma-Aldrich). After defrosting the cells (37oC water bath) 
for culture, cells were washed twice with culture media. Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Sigma D6429) containing 5%FCS, 2mM L-glutamine, 
100U/ml penicillin and 100U/ml streptomycin and sterile cell culture flasks were 
then used to culture hybridomas. Once the hybridomas have expanded and 
adhered to the flask wall, the flask was then filled with (~500ml) of culture 
media, and hybridomas were left to produce antibodies until the media was 
consumed (flask upright). After collecting the supernatants, the supernatants 
were centrifuged, passed via sterile filter (0.22µM mess), and stored at 40oC. 
Culture supernatants were run over a Prosep (Protein-G column 
(Bioprocessing, UK) for monoclonal antibodies purification. The column was 
prepared by running ~10 column volumes of PBS (pH 7.4) containing 0.5M 
Glycine. Then the supernatants were passed through the column followed by 
running 10 column volumes of PBS containing 0.5M Glycine. 0.1M glycine/HCL 
pH2.2-3.5 solution were then used to elute the protein and to be collected as a 
fractions of 5ml and tested for protein content by spectrophotometry. After 
pulling and dialyzing the protein containing fractions against PBS pH 7.4 for 
24hrs, the antibody solution was filtered and the concentration was measured 
by spectrophotometry. The antibodies were then tested by its ability to induce B 
cell cytokines production. 
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2.1.3 Mice and isolation of mouse cells 
2.1.3.1 C57BL/6 and Gal-1-/- mice 	  
Wild type male and female C57BL/6 (H-2Kb) mice and BALB/C (H-2Kd) female 
mice were purchased from Harlan Laboratory, and the donor B6 Kd (H-2Kb) 
mice were a generous gift from Dr. R Pat Bucy (University of Alabama at 
Birmingham, Birmingham, AL, USA). F.Poirier provided Gal-1-/- mice. All mice 
were kept either in a Specific Pathogens Free (SPF) facility, or in a 
Conventional (CV) facility. µMt mice were provided by Jean Langhovne (NIMR, 
Mill Hill, London) and kept in SPF facility. 
The Home Office (UK) approved all mouse protocols utilized in this study. 
2.1.3.2 Genotyping Gal-1-/- mice 
DNA purification from mice tails 	  
Samples were obtained from the tips of Gal-1-/- (Gal-1-/-) mice tails. Tails were 
then placed in sterile 1.5ml microfuge tubes with 300µl DirectPCR Lysis 
Reagent (Viagen Biotech, Inc.) and 0.2mg/ml proteinase K (sigma, UK). After 
overnight incubation at 55oC, the lysates were incubated for 45mins at 85oC. 
Next, the samples were centrifuged at 1400rpm and 1µl was used for 
genotyping (stored at -20oC).  
Primers 	  
3?NeoGal1 5’GTGGTCTTGACAAAAAGAACC 
5?Gal1 5’CTCAGTGGCTAGATCTGTAAAATGG     55.3oC 
3?Gal1 5’TTCTTTGACATTTGAACCCTATACC  
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PCR Programme 	  
Step 1- 94°C 2mins    
 Step 2- 94°C 30s 
 Step 3- 55°C 30s      30 cycles 
 Step 4- 74°C 1min 
 Step 5- 72°C 5mins 
 Step 6- 4°C pause  
PCR Protocol 
 
PCR strips (Abgene) were used to carry out the PCR reactions. The PCR mix 
(50µl) contained 1µl tail lysate, 1.5mM MgCl2 (Promega), 1x Thermophilic 
Polymerase DNA Buffer (Promega), 200µM dNTPs (Promega), 0.4µM primers 
(Sigma) and 2.5 units of GoTaq (DNA polymerase (Promega). 1:5 diluted PCR 
products with DNA loading dye and run on 1% agarose gel (1x Tris-acetate-
EDTA (TAE) buffer (Promega)) containing 3µl ethidium bromide/100ml.  
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2.1.4 Lymphocytes and splenocytes isolation from mice 
spleens and lymph nodes 	  
Spleens and lymph nodes (LNs) were mashed through 70µm nylon cell strainer 
(BD Falcon), and the splenocytes were haemolysed with ammonium chloride 
potassium carbonate (ACK) buffer. Subsequently, the cells were washed 
extensively and re-suspended either in FACS buffer (1x Phosphate Buffered 
Saline (PBS) with 0.4% fetal calf serum (FCS) & 0.4% 
ethylenediaminetetraacetic acid (EDTA)), or complete media, and either stained 
with the mAbs listed above or cultured. The entire process was carried out 
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2.2 Methods 
2.2.1 Cell culture 	  
Complete RPMI 1640 (Sigma-Aldrich, UK) were used for all cell culture 
experiments, supplemented with 10% FCS and 100U/ml penicillin/streptomycin 
(Life Technologies) at 37°C, 5% CO2. 
2.2.1.1 Culture for intracellular staining and cytokines 
detection 	  
Cells were cultured at concentration of 2-5x105 cells per well for 48hrs. PMA 
(50ng/ml), Ionomycin (250ng/ml) and brefeldin A (1:1000) were added for the 
last 4 hours of culture. All cell cultures were carried out in U-bottom 96 plates at 
final volume of 200µl/well. 
2.2.2 Magnetic sorting for cell subsets isolation 	  
Untouched mouse splenic B and CD4+ T cells were isolated using magnetic 
labeled beads. Cells were purified from freshly isolated splenocytes. All 
reagents were purchased from Milteny. 
2.2.2.1 CD43 splenic B cells negative selection (Miltenyi kit: 
130-049-801) 	  
Splenocytes were washed in 50ml falcon tubes with MACS buffer (1xPBS 
containing 0.5% FCS, 2mM EDTA, kept on ice), centrifuged (500g, 4°C, 5mins), 
and the supernatant carefully decanted. Every 107 cell were then re-suspended 
in 90µl of MACS buffer plus 10µl of CD43 beads, mixed, and incubated for 
15mins at 40C. Subsequently, cells were washed with MACS buffer 1ml/107 
cells, centrifuged, and supernatants were decanted. Next, cells were re-
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suspended in 500µl MACS buffer per 108 cells, and passed through MACS LD 
column placed in QuadroMACSTM magnetic fields. LD columns were rinsed 
with 2ml MACS buffer, then cell suspension were applied through the column, 
and the column were washed 3 times with 2ml MACS buffer. Cells were then 
collected in 50ml falcon tube and counted.  
2.2.2.2 CD4 splenic T cells negative selection (Invitrogen: 
114.16D) 	  
Splenocytes were washed in 50ml falcon tubes with MACS buffer, centrifuged, 
and the supernatant carefully decanted. Every 107 cell were then re-suspended 
in 100µl of MACS buffer plus 20µl of FCS and 20µl antibody mix, mixed, and 
incubated for 20mins at 40C. Subsequently, cells were washed with MACS 
buffer 2ml/107 cells, centrifuged, and supernatant were decanted. Next, cells 
were re-suspended in 800µl MACS buffer per 108 cells, and 200µl of depletion 
Dynabeads and incubated for 15mins at 40C on a rotator. The depletion 
Dynabeads (200µl/107 cells) were washed by adding the same volume 
(200µl/107 cells) of MACS buffer, mixed and placed in magnet for 1min, and the 
supernatant were discarded, beads were then re-suspended in the same initial 
volume of MACS buffer. Subsequently, cell suspension were mixed and 1ml 
MACS buffer per 107 cells were added. Then the tube was placed in magnet 
(Dynal-MPC-1) for 2mins, and supernatants were removed (this step was 
repeated twice). Cells were then collected in 50ml falcon tube and counted.  
The depletion Dynabeads (200µl/107 cells) were washed by adding the same 
volume (200µl/107 cells) of MACS buffer, mixed and placed in magnet for 1min, 
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and the supernatants were discarded, beads were then re-suspended in the 
same initial volume of MACS buffer. 
2.2.3 Isolation of B cell subsets by FACS sorting 	  
Purified splenic B cells were suspended in 1ml MACS buffer per 50x106 cells 
(50ml falcon tube). Subsequently, cells were stained with anti-CD21-FITC 
(1:100), anti-CD24-PE (1:1600) and anti-CD23-PE-cy7 (1:200). Cells were then 
incubated for 30mins at 40C, and washed 2 times with MACS buffer. Next, 
every 50x106 cells were re-suspended in 1ml of FACS buffer. DAPI (1:100) was 
added to the cells just before starting the sort to exclude dead cells.   
Sorting took place on a BD FACSAria (BD Biosciences). Doublets were gated 
out. Sorted cells were collected into polypropylene tubes containing sterile 30% 
FCS/PBS. Examples of sorting gating strategies and post-sort B cell subsets 
are given in figures 3.1. 
2.2.4 In vitro experiments 
2.2.4.1 Allo-DCs generation 	  
BALB/c mice, which express H2-kd, ethanol sterilized femurs and tibias Bone 
Marrow (BM) were flushed to obtained fresh BM cells. The cells were 
subsequently passed through 70µm cell strainer (BD Falcon) to obtain single 
cell suspension. Next, cells were incubated with ACK (ammonium chloride 
potassium carbonate) lysing buffer for 10mins to haemolysed erythrocytes. BM 
cells were incubated for 30mins with the supernatants isolated from 53-6.7, YTS 
191, M5/114, RA3-3A1 rat anti-mouse hybridoma cultures. Subsequently, the 
cells were washed twice with RPMI and incubated for 30mins at 4oC on roller 
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with sheep anti-rat Dynabeads and separated through magnetic field. The cells 
were then washed and plated in 24 well plate at 1x106 cells/well in 1ml 
complete media supplemented with 20ng/ml murine recombinant 
granuloctes/macrophage colony-stimulating factor (GM-CFS) (R&D, UK). Plates 
were swirled gently and the fresh complete media containing GM-CFS were 
added on day 2 and 4 of culture. One day before using the allo-DCs, LPS 
(E.coli, Enzo Life Sciences, UK) were added to induce maturation. After 7 days 
of culture, allo-DCs were collected, washed three times, and irradiated for 
10mins.  
2.2.4.2 In vitro B cell subsets suppression assays 	  
Isolated CD4+ T cells were activated through plate bound anti-CD3 antibodies 
(eBiosciences), CD3/CD28 activator beads (Invitrogen, UK), or irradiated allo-
DCs. Anti-CD3 antibodies were diluted (1.5µg/ml) in PBS, and incubated for 2 
hours in round bottomed 96 well plates at 37 ̊C. The plate was then washed 
with PBS. T cells were re-suspended in RPMI (1.5-2x105 cells/well) and added 
to the coated plate, or to non-coated plate in the presences of allo-DCs or 
CD3/CD28 activator beads with non-activated or activated sorted B cell subsets 
(1.5-2x105 cells /well) with or without anti-CD80 Abs (5µg/ml), anti-CD86 Abs 
(5µg/ml), anti-IL-10 Abs (10µg/ml), anti-IL-10 receptor (10µg/ml), lactose 
(10mM/ml) (sigma,UK), or sucrose (10mM/ml) (sigma,UK)  for 48 hours.  
For the activated sorted B cell subsets, B cell subsets were pre-activated with 
CpG/LPS (1µg/ml and 50nM/ml, respectively) for 4 hours in round bottomed 96 
well plates at 37 ̊C, washed 3 times with PBS, and added together with T cells 
into anti-CD3 antibodies. 
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2.2.4.3 B cells activation system 	  
Magnetically isolated B cells (2x105 cells/well) were re-suspended in RPMI 1640 
(10% FCS), and activated for 48 hours with anti-CD40 antibodies (10µg/ml), 
anti-CD40 antibodies plus LPS (1µg/ml) from E.coli (Enzo Life Sciences), anti-
CD40 antibodies plus CpG-B (1nM/ml) (ODN 1826, ALEXIS Biochemicals) and 
CpG plus LPS. After 48 hours of incubation, the cells were labeled with anti-
CD19-APC, anti-CD80-PE and anti-CD86-FITC antibodies and stained for 
intracellular cytokines. 
2.2.5 Mouse experiments  
2.2.5.1 Skin transplant 	  
B6 mice (expressing MHC I H-2Kb) received on their back transplants of 
1cmx1cm bit of tail skin from either MHC I mismatched transgenic C57BL/6 
mice that express H2-kd (B6-Kd) or B6 mice. CD8 cells were depleted by IP 
injection of anti-CD8 antibody (150µg) on day -1, 0 (day of skin graft), +1 and 
every 7 days following the skin graft. Rejection was evaluated 7 days post 
transplant on the basis of escharing (Figure 3.11). 
2.2.5.2 Induction of tolerance to allograft 	  
B6 mice seven days before receiving a skin graft from B6 Kd, receive 25x106 
donor splenocytes (DST) + 250 µg MR1 (anti-CD40L antibody) plus an 
additional injections of 100µg MR1 three days before the graft, on the day of 
graft and four days subsequently. 
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2.2.6 Flow cytometry  	  
Tissues were mashed through 70µm nylon cell strainer, and the erythrocytes 
were haemolysed with ACK buffer. Subsequently, the cells were washed 
extensively and re-suspended (2x106 cells/well) in FACS buffer, and stained 
with the mAbs at a final volume of 50µl, and washed in 200µl FACS buffer. The 
cells were acquired using BD LSR II, and sorted by BD FACSAria II cytometer. 
Analysis was performed by Flowjo software. The staining was performed in 96 
well U-bottomed plates. All in vitro experiments gating were based on live cells 
using fluorescence-based LIVE/DEAD assay	  (Invitrogen, UK).  
2.2.6.1 Surface Staining 	  
In vitro cultured and stimulated cells, or freshly isolated splenocytes were 
washed twice with PBS at 500x g for 5mins. Then, to check the viability of the 
cells live/Dead Fixable blue Dead cell staining kit (invitrogen) were reconstituted 
according to the manufacturers protocol, and 200µl were added per well (for 
every 5 wells, 0.5µl of the reconstituted dye was diluted in 1ml PBS) and 
incubated for 30 minutes at room temperature in dark. Subsequently, cells were 
washed three times with PBS and supernatants were discarded and cells were 
stained with relevant conjugated anti-mouse antibodies. After 20mins of 
incubation at 4oC, cells were washed twice, and fixed with 1x CellFix (1:10 
diluted in dH2O) (BD, UK) for 10 to 15mins at 4oC. Cells were then washed 
twice and re-suspended in 200µl FACS buffer and acquired using BDLSR II or 
BDFortessa, or carried through Fix/Perm steps for intracellular staining (see 
below).   
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2.2.6.2 Intracellular Staining for the detection of cytokines 	  
After initial cells surface staining as described above, cells were fixed via 
20mins incubation at 4oC with 50µl of Cytofix (eBiosciences). Cells were then 
washed with 1x Permwash (10x Permwash in dH20) (eBiosciences), and 
incubated subsequently with 200µl of 1x Permwash for another 20 minutes. 
Next, Supernatant were discarded after spinning the cells at 500x g for 5mins, 
and re-suspended 50µl of relevant anti-mouse Abs diluted in 1x Permwash. 
Following 20mins of incubation at 4oC, cells were washed twice with 1x 
Permwash and once with FACS buffer. BD LSR II of BDFortessa was used to 
acquire the cells; analysis was done by Flowjo software. 
2.2.6.3 Antibodies detection  	  
Total IgG was measured in the sera of B6 mice that had received B6-Kd skin 
grafts by incubating the sera with H2-Kd expressing BALB/c splenocytes. 
Binding of anti-Kd antibody to H2-Kd on CD3+ T cells was then detected by flow 
cytometry. The BALB/c splenocytes (2.5x105 cells/well) were blocked by anti-
CD16/CD32 antibodies (eBiosciences) and then labeled by anti-CD3-PE 
followed by adding diluted sera (1:10; 1% Bovin Serum Albomin (BSA)/ PBS). 
After 20 minutes of incubation, total anti-IgG-FITC antibodies (Sigma 
Immunochemicls) were incubated with the cells for 20 minutes. The cells were 
acquired by BD LSR II or BDFortessa and analyzed by Flowjo software. 
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2.2.6.4 fluorescent in-situ hybridization (FISH-Flow) 	  
Stool samples were collected from mice either by stressing the animals or 
directly after culling them. Samples were stored at -80oC. Samples were first 
fixed by adding 500µl PBS to 0.05g samples, and 3-4 glass beads homogenise 
with tissue lyser for 5mins. The sample was then aliquot (200µl) and 600µl of 
4% paraformaldehyde solution (PFA) was added, and incubated overnight at 
4oC. Subsequently, the samples were permeabilised by spinning the samples at 
500x g for 1min to remove debris, 250µl of the fixed bacterial solution were then 
added to 200µl PBS, centrifuge at 8000x g for 3mins and the supernatants were 
discarded. Next, 1ml of Tris-EDTA were added followed by 3mins centrifugation 
at 8000x g. After discarding the supernatants, 1ml of Tris-EDTA with lysozyme 
(20mg lysozyme in 20ml Tris-EDTA) were added, mixed, incubated for 10mins 
at room temperature and centrifuge at 8000x g for 3mins. The supernatants 
were discarded, 1ml of PBS were then added, samples vortexed and 
centrifuged as previous. After permeabilisation the samples were hybridised. 
First, 1ml of hybridisation buffer (NaCl 5M, Tris HCl 1M pH8, SDS 20%, 
Formamide 12ml and 30ml dH2O) were added, vortexed, centrifuged as above 
and the supernatants were discarded. 240µl hybridisatiion buffer were then 
added and 40µl of samples were transferred into wells. 10µl of the relevant 
probe (section 2.2) were added and incubated overnight at 37oC. Next morning, 
150µl of hybridisation buffer were added, centrifuged at 4000rpm for 10mins, 
and the supernatants were discarded. Subsequently, the samples were washed 
by 200µl washing solution (NaCl 5M, Tris HCl 1M pH8, EDTA 0.5M pH8, SDS 
20% and 47.8ml dH2O), mix, and incubate for 20mins at 39oC. The plate was 
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then centrifuged as above and 200µl PBS was added and the samples were 
acquired using BDLSR II.      
2.2.7 ELISA 
2.2.7.1 IL-10 ELISA 	  
After cells culture and stimulation, supernatants were collected before adding 
PMA, ionomycin and brefeldin A, and kept at -80oC until use. 100µl/well of IL-10 
capture antibody was incubated overnight at 4oC at concentration of 5µg/ml in 
PBS/Tween (PBS/ 0.05% Tween-20) in 96 well MaxiSorp plates (NUNC) to coat 
the plate. Subsequently, plates were washed 5 times with PBS/Tween and 
blocked with 200µl per well 2% BSA in PBS for 1 hours at room temperature 
(RT). After washing the plates 5 times with PBS/Tween, recombinant IL-10 
standards were serially diluted (1:2) with a top concentration of 4000pg/ml and 
bottom standard of 31.25pg/ml, and 100µl of 1:4 diluted supernatants and 
prepared standards were added and incubated for 2 hours at RT. Plates were 
then washed 5 times with PBS/Tween and 100µl of biotinylated IL-10 detection 
antibody (0.5-2µg/ml) were added and the plates were incubated 1 hours at RT. 
After 5 washes, 100µl/well of streptavidin-horseradish peroxidase was added 
and incubated for 30mins at RT. Plates were washed for 14 times, and 100µl of 
substrate solution (3,3’,5,5’-tetramethylbenzidine (TMB)) were added for 11mins 
at RT, and the reaction were stopped by adding 50µl of stop solution (450ml 
dH2O plus 20ml H2SO4), and the plates were read at 450nm. 
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2.2.7.2 Flowcytomix 	  
Standards and reagent were made up according to manufacturers protocol 
(eBiosciences, UK). Supernatants were collected after stimulating cells for 
42hours with LPS, CPG and anti-CD40 mAb (section 2.2.4.3), and stored at -
80oC until use. 25µl of Standard mixture dilutions 1 to 7 and samples were 
transferred into tubes plus an additional blank tube (25µl assay buffer), and 25µl 
of beads mixture and 50µl of Biotin-conjugate mixture were added to all tubes, 
mixed, and incubated for 2 hours at RT. Subsequently, 1ml of assay buffer were 
added and the tubes were centrifuged for 5mins at 200xg (this step was 
repeated). After discarding the supernatants, 50µl of streptavidin-PE solution 
were added, mixed and incubated at RT for 1 hour in dark. Tubes were washed 
twice as previously, and 500µl assay buffer were added and the samples were 
acquired using BDLSR II. Flowcytomix pro 2.4 software was used for analysis. 
The kit was a grateful gift from eBiosciences.  
2.2.8 Western Blot 	  
Isolated B cells were washed with PBS, and the pellets were stored at -80°C. 
The dry pellets were lysed in 50µl lysis buffer per 5x105 cells for one hour on a 
rotator at 4 ̊C. The lysis buffer consist of 20mM Tris-base (sigma), 5mM EDTA 
(Gibco BRl), 1% NPHO, 2.5% protease inhibitor cocktail (sigma), 0.5% PMSF 
(sigma) and 0.05% soyabean (sigma). After one hour of incubation, the lysed 
cells were spun down in a centrifuged (13000rpm/5 minutes), and the 
supernatant was transferred into a new tube. The lysates were then run 
overnight through a sodium dodeyl sulfate-polyacrylamide gel by 
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electrophoresis (SDS-PAGE). The proteins were then transferred into 
immobilon-P transfer membrane (Millipore), using a semidry transfer system. 
The membranes were subsequently probed with mouse anti-human galactin-1 
mAb (Biotech) in PBS with 5% milk + 0.2% Tween 20 (sigma) for 1hour. Goat 
HRP-conjugated rabbit anti-mouse IgG (Bio-RAD) were then added and 
incubated for 1hour, and developed with ECL plus western blotting detection 
reagent (GE Healthcare). Regulatory T cells were obtained from cell line, and 
used as a positive control. 
2.2.9 Signaling pathways protocols 
2.2.9.1 Cells activation and fixation  	  
Isolated B cells were washed with cold PBS, and 0.5x106 cells (50µl) per well 
were stimulated either with 100µl LPS (2µg/ml) or CPG (300nM/ml) at 37oC 
either for 0, 10,30, 45, and 60mins (for P38 & ERK pathways) or 0, 20, 45 and 
90mins (NF-κB pathway). The cells were then fixed with 50µl of 4% 
formaldehyde (10% stock, sigma, UK) on ice for 10mins, centrifuged and 
washed. Cells were then suspended in 1:100 diluted anti-CD19 mAbs for 
30mins.   
	  2.2.9.2 P38 & ERK 	  
After staining with anti-CD19 mAb, the cells were permeabilised in 200µl of 90% 
methanol (sigma, UK) for 30mins on ice, washed twice with incubation buffer 
(1% BSA in PBS), and the primary antibodies (p38 and ERK) were then added 
for one hour at RT. After washing twice, the secondary antibodies were added 
for 30mins. Cells were then washed twice and acquired by BDLSR II.  
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2.2.9.3 NF-κB 	  
After staining with anti-CD19 mAb, the cells were incubated for 20mins with 
anti-NF-κB Ab diluted in prepared permeabilised buffer (0.1% triton X-100, 2% 
FCS, 0.1% azide and PBS). Then, the cells were washed and re-suspended in 
50µl of the secondary antibodies for 15mins at room temperature. Finally, cells 
were washed and 50µl PBS and DAPI (1:100) were then added just before 
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Chapter 3 
B cells are mainly known for their ability to produce antibodies, but they also 
contribute to antibody-independent mechanisms such as antigen presentation 
and cytokine production [125]. Therefore, they have the potential to shape the 
immune response [275,276,277]. B cells are in fact involved in the early stages 
of Th subsets differentiation [260]. A subpopulation of B cell, T2-MZP B cells, 
has been found to play a protective role in various murine models of chronic 
inflammation [146,149]. In arthritis, mice with active form of the disease (DBA/1 
mice) were protected upon the adoptive transfer of T2-MZP B cells isolated 
from naïve mice [146]. In lupus, the adoptive transfer of anti-CD40 mAb 
activated T2-MZP B cells in vitro improved MRL/ipr mice survival rate [149]. 
These studies have suggested that T2-MZP B cells mainly act through the 
production of IL-10 [146,149].  
Gal-1 is classified as immunoregulatory molecules that can regulate cell growth, 
proliferation, mitosis and apoptosis as well as many other functions 
[187,190,191]. For example, it has previously been shown that Gal-1 
expression is up regulated following Treg cell activation through their TCR 
receptor and that Gal-1 plays a key role in Treg function [196]. Moreover, it was 
found that blocking Gal-1 by anti-Gal-1 mAbs in vitro inhibited the suppressive 
function of the Treg cells in humans [196]. Additionally, other studies have also 
shown that Gal-1 can play a key role in B cell function, in term of their 
immunoglobulin production [205], development [206], and their influence on T 
cells [207]. For example, in Trypoansoma cruzi infection model, IFN-γ, but not 
IL-10 production by Con-A activated T cells was significantly decreased upon 
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adding Gal-1 purified from infected B cells [207].  
The aim of this chapter was to examine whether T2-MZP B cells had a role in 
transplantation, and explore the possible mechanisms underlying this potential 
including Gal-1 involvement. 
Note   
1- For all the results in chapter 3, 4 and 5 the cells counts per FACS 
acquisition was between 20x103 to 50x103 cells.  
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3.1 B cells isolated from SPF mice were unable to 
suppress CD4+ T cell TNF-α  expression in vitro.  	  
T2-MZP B cells with a regulatory function and which are able to suppress CD4+ 
T cell cytokine production, in particular the expression of TNF-α, have 
previously been reported in autoimmune model [146,149]. To determine 
whether B cells, and particularly T2-MZP B cells had similar capacity in 
transplantation, I cultured FACS purified B cell subsets (T1, T2-MZP, MZ and 
FO B cells) with CD4+ T cells for two days in vitro. B cells were magnetically 
isolated from the spleens of C57BL/6 (B6) mice (maintained in the SPF facility) 
and sorted by BD FACSAria into subsets (Figure 3.1 A & B). B cell subsets 
were co-cultured with CD4+ T cells (1:1 ratio) in the presence of CD3/CD28 
activator beads (1:1); plate bound anti-CD3 Abs (1µg/ml) or irradiated allo-DCs 
(25 T cell: 1 all-DCs) for 48 hours. Cells were incubated with PMA and 
Ionomycin and brefeldin A for the last 4 hours of culture. TNF-α expression was 
measured in CD4+ T cells, and IL-10 expression in B cells, by intracellular 
staining and flow cytometry. Although MZ B cells, and to some extent the other 
B cell subsets expressed IL-10 (Figure 3.2 A & B), no B cell subset exerted any 
regulatory effect on T cells when they were activated with CD3/CD28 activator 
beads (Figure 3.3 A & B), plate bound anti-CD3 Abs (Figure 3.3 C) or allo-DCs 
(Figure 3.3 D). Instead there was a higher percentage of TNF-α+ CD4+ T cells in 
co-cultures with B cells at 48 hours compared to CD4+ T cells cultured in the 
absence of B cells (Figure 3.3). 
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In summary, B cell subsets exerted no regulatory effect on activated CD4+ T 
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3.2 Pre-activation of B cell subsets with IL-10 
promoting stimuli did not induce regulatory capacity 
in T2-MZP B cells. 	  
Given that activating B cells with anti-CD40 antibody in vitro resulted in the 
recovery of IL-10 mediated Breg function in MRL/lpr mice [149], here, I 
addressed whether pre-activating B cells in vitro with stimuli shown to promote 
the expression of IL-10 could induce a regulatory ability in B cells in our model. 
After stimulating B cell subsets with combinations of LPS, CPG, LPS/CPG and 
anti-CD40 antibody for 48hrs, B cells showed the highest IL-10 expression 
when activated with LPS/CPG (representative FACS plots of IL10 expression in 
Figure 3.4 A). Therefore, LPS/CPG combination was selected to treat B cells 
before co-culture with T cells (Figure 3.4 A). FACS purified B cell subsets were 
cultured with CPG plus LPS for 4 hours, washed, and then co-cultured with 
CD4+ T cells in the presence of plate bound anti-CD3 antibodies (1µg/ml) for 48 
hours. Cells were incubated with PMA and Ionomycin and brefeldin A for the 
last 4 hours of culture. TNF-α expression was measured in CD4+ T cells, and 
IL-10 expression in B cells, by intracellular staining and flow cytometry. Figure 
3.4 B show that co-culture of CPG/LPS-activated B cells with anti-CD3-
activated CD4+ T cells resulted in a higher percentage of TNF-α+ CD4+ T cells 
than if CD4+ T cells were cultured with anti-CD3 alone. Although CPG/LPS pre-
activated T2-MZP B cells were unable to suppress CD4+ T cell TNF-
α expression, co-culture of CD4+ T cells with T2-MZP B cells resulted in the 
lowest percentage of TNF-α+ CD4+ T cells compared to CD4+ T cells cultured 
with the other B cell subsets (Figure 3.4.B). 
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In addition, I investigated whether the B cells were still expressing IL-10 after 
culture with anti-CD3 activated T cells. I found that after 48 hours culture with 
CD4+ T cells a higher percentage of MZ B cells expressed IL-10 than T2-MZP 
cells, while IL-10 was not expressed by Transitional-1 (T1) or Follicular B cells 
(FO) (Figure 3.4 C). Although T2-MZP and MZ B cells produced IL-10, TNF-α 
expressions were higher than CD4+ T cells cultured in the absence of B cell 
subsets. These results suggest that there is no correlation between IL-10 
expressions by CPG/LPS activated B cells and their capacity to suppress CD4+ 
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Figure	   3.4	   Pre-­activation	   of	   B	   cell	   subsets	   with	   IL-­10	   promoting	   stimuli	   did	   not	   induce	   regulatory	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3.3 B cells isolated from mice maintained in CV 
facilities suppress TNF-α  expression by CD4+ T cells. 	  
It has previously been reported that the level of sterility in which the mice are 
kept can influence the regulatory capacity of B cells; a subset of B cells that 
was suppressive in CV facilities was reported to lack this capacity in SPF 
facilities [274]. I thus wanted to investigate whether T2-MZP B cells would 
similarly recover their suppressive capacity if isolated from mice kept in less 
sterile conditions. To investigate whether B cells obtained from mice in the CV 
facility would be able to suppress TNF-α expression by CD4+ T cells I isolated B 
cells from the spleens of CV maintained B6 mice by magnetic sorting. B cell 
subsets were then FACS sorted, and co-cultured with CD4+ T cells in the 
presence of allo-DCs derived from BALB/c mice (25:1) or CD3/CD28 activator 
beads (1:1) for 48 hours. PMA, Ionomycin and brefeldin A were added for the 
last 4 hours of culture. TNF-α and IL-10 were measured by intracellular 
staining. The results showed that T2-MZP B cells isolated from CV maintained 
B6 mice were able to significantly suppress allo-DCs activated CD4+ T cell TNF-
α expression, T1 B cells were also suppressive but the difference with the 
culture without B cells was not significant (Figure 3.5 A & B). T2-MZP B cells 
were also able to significantly suppress CD3/CD28 bead activated CD4+ T cell 
TNF-α expression, while although MZ B cells suppressed TNF-α+ CD4+ T cells 
the difference with the culture without B cells was not significant (Figure 3.5 C). 
Within this assay B cell survival rates were measured, and the results showed 
that no differences between B cell subsets survival (Figure 3.5 D & E).   
As with B cell - T cell co-cultures using cells isolated from SPF maintained mice 
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there was no correlation between IL-10 expression by B cells and their 
suppressive capacity when B and T cells were obtained from the CV facilities 
(Figures 3.5 and 3.6) Although there were significantly fewer IL-10+ T2-MZP B 
cells than IL-10+ MZ B cells in co-cultures with both allo-DCs and bead 
stimulated CD4+ T cells, T2-MZP B cells could significantly suppress beads and 
allo-DCs activated CD4+ T cells TNF-α expression while MZ B cells only 
suppressed bead activated T cells but the difference with the culture without B 
cells was not significant (Figure 3.6). 
To summarize, there was a significant difference in the suppressive capacity of 
B cells isolated from CV maintained mice compared to SPF maintained mice 
(figure 3.7 A). B cells, in particular T2-MZP B cells, isolated from CV maintained 
B6 mice were able to suppress allo-DC or CD3/CD28 beads activated CD4+ T 
cell TNF-α expression while the equivalent subsets isolated from SPF 
maintained mice could not. There was however no significant differences in the 
ability of B cells to express IL-10 between B cells isolated from mice maintained 
in SPF or CV facilities (Figure 3.7 B). 
These results suggest that T2-MZP B cells are likely to include a regulatory B 
cell subset in these mice since they are the ones that suppress allo-stimulated 
CD4+ T cells. Therefore, I sought next to determine the possible mechanism 
that could be involved in T2-MZP B cell regulatory function as IL-10 seems not 
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3.4 The suppressive capacity of T2-MZP B cells 
requires the expression of Gal-1 and CD80/CD86 
molecules. 	  
Gal-1 has been shown to have an immunoregulatory role in the immune 
responses [187,190,191]. Therefore, I sought to determine whether Gal-1 plays 
a role in T2-MZP B cell suppressive capacity. First, to confirm whether B cells 
express Gal-1, I initially examined its expression in total B cells by western blot. 
B cells were isolated from three naive B6 mice by magnetic sorting, and the 
cells (5x105 cells) were then lysed and the lysates used for sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) analysis. 
Subsequently, the gel was passed through the steps that have been described 
previously in the methods for western blot preparation. As shown in Figure 3.8, 
B cells express Gal-1.  
To examine the difference in the ability of B cells isolated from Gal-1-/- mice kept 
in the SPF and CV facilities to express IL-10. B cells were isolated from Gal-1-/- 
and B6 (as a control) mice housed in the SPF and CV facilities and stimulated 
with various stimuli (LPS, CPG and anti-CD40 mAb) for 48 hours. PMA and 
Ionomycin and brefeldin A were added for the last 4 hours of culture. IL-10 
expression was measured in B cells, by intracellular staining and flow 
cytometry. These primary results showed that B cells isolated from Gal-1-/- mice 
kept in the SPF and CV facilities expressed IL-10 at the same levels (Figure 3.9 
A). 
Then, to examine Gal-1 role in T2-MZP B cell suppressive function, splenic B 
cells were magnetically isolated from B6 and Gal-1-/- mice housed in the CV 
facilities. Subsequently, B cell subsets were FACS sorted, and co-cultured with 
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allo-DCs (irradiated) and CD4+ T cells (isolated from naïve B6 mice) for 48 
hours. PMA and Ionomycin and brefeldin A were added for the last 4 hours of 
culture. TNF-α expression was measured in CD4+ T cells, and IL-10 expression 
in B cells, by intracellular staining and flow cytometry. T2-MZP B cells isolated 
from Gal-1-/- mice lost the ability to suppress CD4+ T cells TNF-α expression 
compared to B cells from B6 mice (Figure 3.9 B and C). Again, there was no 
significant difference in the ability of B cell subsets between the two strains of 
mice to express IL-10 (Figure 3.9 D). These results suggest that the capacity of 
T2-MZP B cells to suppress allo-DCs activated T cells is Gal-1 dependent and 
does not correlate with the capacity of B cells to express IL-10. 
In addition, it has been reported that B cells provide essential signals for the 
activation and proliferation of autoreactive CD4+ T cells via CD80 and CD86 
mediated interactions [136]. To examine the role of CD80 and CD86 molecules, 
B cells were isolated from B6 mice housed in CV facilities by magnetic sorting 
and the B cell subsets were FACS sorted. The B cell subsets were co-cultured 
with CD4+ T cells stimulated by CD3/CD28 beads with and without anti-CD80 
and anti-CD86 neutralizing antibodies (5µg/ml) for 48 hours. Subsequently, 
PMA and Ionomycin and brefeldin A were added for the last 4 hours of culture. 
TNF-α expression was measured in CD4+ T cells by intracellular staining and 
flow cytometry. I found that T2-MZP B cells lost their suppressive ability in the 
presence of anti-CD80 and anti-CD86 neutralizing Abs (Figure 3.10 A), whereas 
neutralizing CD80 and CD86 molecules did not affect the suppressive function 
of MZ B cells (Figure 3.10 B). This result demonstrates that T2-MZP B cells 
require CD80 and CD86 molecules to exert their regulatory effect.  
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In summary, the inhibitory effect of T2-MZP B cells depends on the presence of 
Gal-1 and on cell contact through CD80 and CD86. However the suppressive 
capacity of MZ B cells on CD3/CD28 bead activated CD4+ T cells seems not to 
be associated with CD80/CD86 molecules. 
Moreover, our attempt to inhibit IL-10 and the extracellular Gal-1 by adding anti-
IL-10 and anti-IL-10 receptors neutralizing antibodies and lactose (to block Gal-
1) to our suppressive assay has failed. One of the reasons was the direct effect 
of the antibodies and the lactose on T cell activation. As shown in Figure 3.11 
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Figure	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Figure 3.11 The suppressive capacity of T2-MZP B cells requires the expression of Galectin-1 and 
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3.5 T2-MZP and T1 B cells isolated from mice kept in 
the CV facilities can prolong MHC I mismatched skin 
graft survival.  	  
The adoptive transfer of T2-MZP B cells has previously been reported to 
suppress the development of several murine experimental models of 
autoimmunity. For instance, adoptive transfer of T2-MZP B cells suppressed 
CIA and Lupus [146, 149]. Moreover, a recent report in a transplantation model 
showed that the transfer of splenic TIM-1+ B cells, but not TIM-1- B cells, which 
were isolated from anti-TIM-1 treated islet transplant recipient mice 14 days 
post transplant, were able to prolong the survival of islets following adoptive 
transfer to B cell deficient JHD mice [173]. Therefore, I sought to determine if B 
cells, in particular T2-MZP B cells had similar suppressive capacity in our 
model. Our in vitro data suggested that B cells from the SPF facility would not 
be able to prolong graft survival but that B cells from the CV facilities might. To 
investigate this possibility, T1, T2-MZP, FO and MZ B cells were FACS sorted 
from the spleens of naïve B6 mice maintained in SPF facilities and 1x106 cells 
(maximum number of T2-MZP B cells acquired after sorting) of each subset 
were adoptively transferred (IV) to naïve B6 mice. The day after B6 mice (H-2b) 
received 1cmx1cm dorsal grafts of tail skin from MHC I mismatched transgenic 
B6 mice that express H2-Kd (B6-Kd). CD8+ T cells were depleted by IP injection 
of anti-CD8 antibody on day -1, 0 (day of skin graft), +1 and every 7 days 
following the skin graft. Grafts were said to be rejected following the formation 
of a hard black eschar (Figure 3.12). The results in Figure 3.13 show that the 
adoptive transfer of B cell subsets isolated from SPF maintained mice did not 
prolong skin graft survival compared to control mice for any of the transferred 
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subsets, confirming our hypothesis about SPF B cells. 
Given that the in vitro data suggested that maintenance of mice in CV facilities, 
as opposed to SPF facilities, allows the isolation of functional regulatory B cells, 
I repeated these experiments using mice housed in CV facilities. As skin 
transplant experiments are usually carried out in SPF facilities I first examined 
the feasibility of conducting skin grafts in CV facilities given the higher risk of 
skin infection, which could result in unexpected rejection. Therefore, I performed 
skin transplants on two groups of B6 mice. One group received B6 Kd skin and 
one received B6 skin, and skin survival was monitored for 100 days. I found that 
B6 Kd skin recipients rejected within 8 to 9 days (earlier than the rejections 
observed with B6 Kd skin recipients maintained in SPF facilities (13 days)), 
while B6 skin recipients had still not rejected the skin graft by day 100 (Figure 
3.14 A). These results suggested that the greater risk of infection was not a 
barrier to performing skin transplantation experiments in CV facilities.  
Given that, I repeated the adoptive transfer experiments I had carried out in the 
SPF facilities in the CV facilities. B6 mice received injections of 1 x106 T1, T2-
MZP, MZ or FO B cell subsets one day before skin transplant as above. In 
addition, I compared the effects of injecting B cells isolated from B6 or Gal-1-/- 
mice (controls were injected with PBS). As above recipient B6 mice were 
depleted of CD8+ T cells by injections of anti-CD8 at day’s -1, 0 (day of skin 
graft), +1 and every 7 days following the skin graft. To exclude rejection due to 
infection, I added as control a group of B6 mice transplanted with B6 skin in 
every experiment performed. In agreement with our in vitro results, T2-MZP 
and, T1 B cells significantly prolonged the survival of B6-Kd skin graft compared 
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to control mice mean graft survivals were 15 days, 13 days, and 10 days for T2-
MZP, T1 and controls respectively. Although transfer of MZ B cells significantly 
prolonged skin survival (mean survival 12 days) compare to the control, 
adoptive transfer of T2-MZP B cells resulted in significantly longer graft survival 
compared to MZ B cells. In contrast, FO B cells did not prolong allograft survival 
(mean 10) (Figure 3.14 B). Moreover, the involvement of Gal-1 in T2-MZP B 
cells regulatory function was confirmed in this in vivo experiment. Adoptive 
transfer of Gal-1-/- T2-MZP, T1 or MZ B cells did not prolong B6 Kd skin survival 
compared to controls. Recipients that received Gal-1-/- T2-MZP B cells rejected 
the graft (mean survival 10 days) at the same time as the control group (mean 
survival 15 days) (Figure 3.14 B). Although the absence of Gal-1 has affected 
T1 and MZ B cells to lose their capacity to prolong skin graft survival, it was not 
significant compared to the WT T1 and MZ B cells (mean survival 9 & 10, 
respectively). 
In addition, serum was collected from these mice at 30days post-transplant 
(from both SPF and CV experiments) in order to evaluate any differences in 
allo-specific IgG levels in these animals. There was no significant difference in 
the alloantibody levels in the serum between mice receiving the different B cell 
subsets (Figure 3.13 B and 3.14 D). 
Collectively, T2-MZP, T1 and MZ B cells prolonged graft survival, however, T2-
MZP B cells provided significantly better survival compared to MZ B cells (look 
at the discussion for T1). These B cell subsets lost their capacity to prolong skin 
graft survival when isolated form Gal-1-/- mice. 
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3.6 No differences in B cell subset proportions, but 
significant differences in the percentages of memory 
CD4+ & CD8+ T cells in mice maintained in CV & SPF 
facilities. 	  
Next, I wanted to determine if there were obvious immunological differences 
between mice kept in CV and SPF facilities that might have explained the 
difference in the capacity of B cells to prolong skin graft survival. First I 
addressed whether the mice being kept in SPF or CV facilities influenced B and 
T cell subsets proportions. Spleens and lymph nodes were collected from mice 
in both facilities, and the cells were incubated with anti-CD19, anti-CD21, anti-
CD23 and anti-CD24 Abs for flow analysis of B cell subsets. To investigate any 
difference in T cell subsets, I stained the lymphocytes and splenocytes with 
anti-CD8, anti-CD4, anti-CD25, anti-CD44 and anti-CD62L Abs to identify 
memory and naïve CD4+ and CD8+ T cells. The results showed no differences 
in the proportions of the various B cell subsets in the spleens and lymph nodes 
of mice maintained in SFP and CV facilities (Figure 3.15 A). On the other hand, 
there were significantly higher percentages of total CD8+ T cells in the spleens 
of B6 mice maintained in SPF facilities compared to mice maintained in CV 
facilities (Figure 3.15 B & C). In addition, in the lymph nodes, CV mice 
expressed significantly higher percentages of total CD4+, memory CD4+ and 
CD8+ T cells (Figure 3.15 C & E). These results suggest that T cells have been 
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3.7 T & B cells isolated from mice maintained in CV 
facilities express higher levels of co-stimulatory 
molecules compared to mice kept in SPF facilities. 	  
I next evaluated the expression of co-stimulatory molecules on CD8+, CD4+ and 
CD19+ cells, in the spleens and lymph nodes of mice that have been kept in the 
CV and SPF facilities. In the spleens, CD4+ and CD8+ T cells expressed 
marginal but significantly higher levels of CD80 molecule when isolated from 
mice that have been kept in CV facilities compared to those maintained in SPF 
facilities (Figure 3.16 A & B). The differences were small however and whether 
they are physiologically relevant is unclear. In addition, there was a trend for a 
lower level of expression of CD80 molecule on the same cells, although this 
was not significant (Figure 3.16 A & B). CD4+ and CD8+ T cells isolated from 
lymph nodes of mice maintained in CV facilities expressed significantly higher 
levels of co-stimulatory molecules compared to mice maintained in SPF 
facilities, but again whether they are physiologically relevant is unclear (Figure 
3.16 C). B cells expressed significantly higher levels of MHC I and II in 
lymphocytes isolated from mice that have been kept in CV facilities compared 
to cells obtained from mice maintained in SPF facilities (Figure 3.16 D).  
These results suggest that cells from mice maintained in CV facilities are more 




	   120	  
	  







































































































































































CD4 (Spleen) CD8 (Spleen)
CD4 (LNs) CD8 (LNs)
CD19 (Spleen) CD19 (LNs)
SPF mice
CV mice
	   121	  
3.8 Differences in the response to in vitro activation of 
splenocytes isolated from mice kept in SPF and CV 
facilities. 	  
I next sought to determine whether B and T cells isolated from mice maintained 
in CV and SPF facilities responded differently upon activation. In this 
experiment we activated splenocytes obtained from mice maintained in CV and 
SFP facilities with PMA and Ionomycin for 5 hours. CD69, CD86, MHC I, and 
MHC II molecules were measured on B and T cells. In addition the expression 
of IFN-γ, IL-10 and TNF-α by T and B cells were assessed by intracellular 
staining and flow cytometry. The results showed that upon re-stimulation in vitro 
with PMA and ionomycin T cells isolated from mice maintained in CV facilities 
tended to express higher levels of CD69 and MHC I molecules compare to mice 
from SPF facilities. B cells obtained from CV facilities and re-stimulated in vitro 
with PMA and ionomycin tended to express higher levels of CD69, MHC I and 
MHC II molecules, but expressed significantly lower levels of CD86 molecule 
compared to cells isolated from mice that have been kept in the SPF facilities 
(Figure 3.17 A-E). 
In addition, B cells isolated from mice maintained in SPF facilities were found to 
express significantly higher levels of IFN-γ and TNF-α compared to those 
isolated from CV facilities. On the other hand, T cells obtained from mice kept in 
the CV facilities expressed significantly higher level of IL-10 compared to those 
isolated from mice maintained in SPF facilities (Figure 3.18 A-D).  
These results suggest that B cells from CV mice might be more activated than 
SPF cells, and that there is a Th1 bias in SPF mice compared to CV mice. 
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Figure	  3.18	  Differences	  in	  the	  cytokines	  response	  to	  in	  vitro	  activation	  of	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  from	  mice	  kept	  in	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  and	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  facilities. 
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3.9 Mice kept in CV facilities have different balance of 
microbiota and higher percentage of GC B cells than 
mice housed in SPF facilities. 	  
Previous reports have shown that commensal microbiota, in particular some gut 
microbiota, influence the development of immune responses and protect from 
diseases [278,279]. However, how and whether commensal microbiota 
contribute in the development of such atopic diseases is not clear. Also, it has 
been reported that the differences in gut microbiota has affected stimulated and 
non-stimulated B cells isolated from the spleens and peyer’s patches (PPs) of 
mice kept in CV facilities to secrete higher levels of Ig compared to mice kept in 
germ free facilities, suggesting that microbiota has an impact on B cells function 
[280]. Therefore, I sought to determine if the remarked variations I found in the 
make up of the immune system and cytokines profile between mice housed in 
the SPF and CV facilities are associated with variation in the make up of their 
gut microbiota, and if these changes have any influence on the level of B cell 
activation (GC B cells). Here, mice were kept in SPF and CV facilities for 8 
weeks, subsequently, they were sacrificed and fecal samples, spleens, lymph 
nodes and PPs were collected. Fecal samples were used to identify the gut 
microbiota using FISH (see M&M), while the spleens, lymph nodes and PPs 
were used to determine the percentage of GC B cells. Figure 3.19 A shows that 
mice housed in CV facilities expressed significantly different levels of gut 
microbiota, and their spleens and PPs also expressed higher levels of GC B 
cells (Figure 3.19 B), compared to mice kept in SPF facilities. 
Collectively, housing the mice under different level of sterility has resulted in the 
observed differences in the gut microbiota and the levels of B cells activation, 
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Figure 3.19 Mice kept in CV have di!erent balance of microbiota and di!erent level of GC B cells than mice 
housed in SPF facilities. Spleens, LNs, PPs & fecal samples were collected from B6 mice kept in SPF & CV facilities. 
(A) Histogram showing the gut microbiota in mice kept in SPF & CV facilities. (B) Histogram showing the percent-
ages of GC B cells in spleens, LNs & PPs isolated from mice housed in SPF & CV facilities. Graphs show mean± SEM, 
n=3. Statistics were calculated by t test, *P<0.05 & **P<0.005.
A)
B)
	   127	  
Discussion 	  
Up to date, the regulatory role of B cells in transplantation has not been 
extensively investigated. Indeed, B cells have been primarily thought of as the 
source of alloantibodies that activate complement and varieties of effector cells 
[281]. The presence of antibodies may simply reflect B cell activation, however, 
B cell effector mechanisms in the allo-response may be antibody independent. 
B cells do not influence the immune response solely through the production of 
antibodies, but also via cytokine production or by presenting antigens [125]. 
In this chapter, I focused on the regulatory role of B cells in transplantation. 
Furthermore, I have provided insights into the mechanisms by which B cells 
could mediate regulation in transplantation. 
In a CIA model, Evans and colleagues compared the percentages of IFN-γ 
expressing CD4+ T cells when cultured alone and when co-cultured with B cell 
subsets. They found that among all B cell subsets, T2-MZP B cells were the 
only subset capable of down regulating IFN-γ expressing CD4+ T cells. 
Furthermore, they studied the correlation between IL-10 and T2-MZP B cell 
suppressive function, and found that T2-MZP B cell function in a contact-
independent and IL-10-dependent manner [146]. Moreover, it has been 
documented that T2-MZP B cells were also shown to be regulatory in the 
MRL/lpr mouse model, and also that the equivalent population in humans has 
been associated with tolerance [149]. 
Therefore I sought to determine whether T2-MZP B cells could provide the 
same protective role in transplantation as they do in autoimmune models, and 
whether this role is IL-10 dependent as reported previously. I have shown in this 
	   128	  
chapter that B cell subsets isolated from B6 mice maintained in the SPF facility 
did not suppress TNF-α expressing CD4+ T cells obtained from B6 mice living in 
the same facility and stimulated in vitro by CD3/CD28 beads, plate bounded 
anti-CD3 antibody, or allo-DCs (Figure 3.3). The lack of regulation by B cells 
was independent from the capacity of the different B cell subsets to produce IL-
10 (Figure 3.2). Since activating the T2-MZP B cell subset in lupus model with 
anti-CD40 mAbs resulted in an enhanced suppressive effect compared to the 
other B cell subsets [146149], I tested whether T2-MZP activated B cell subset 
stimulated with LPS and CPG can regulate T cell responses. Although activated 
T2-MZP B cells expressed the higher level of IL-10 compared to non-activated 
T2-MZP B cells (Figure 3.4 A), no regulatory function was exerted by this B cell 
subset or any other B cell subsets (Figure 3.4 B). Moreover, although MZ B 
cells expressed highest levels of IL-10 they still did not show any capacity to 
regulate TNF-α  production by T cells (Figure 3.4 B & C). These data suggest 
that under these conditions there is no regulatory effect exerted by CPG/LPS 
stimulated IL-10+ B cells on activated TNF-α expressing CD4+ T cells. 
Additionally, the adoptive transfer of any of the B cell subset isolated from B6 
mice housed in the SPF facility, into B6 recipients of B6-Kd skin grafts 
maintained in the same facility, failed to prolong skin graft survival (Figure 3.13). 
According to the hygiene hypothesis, which is also known as microbial 
exposure hypothesis, the improved hygiene and sanitary levels in developed 
countries lead to the rise in allergies and autoimmune diseases [282]. This 
hypothesis focuses on the role of microorganisms in tolerising the immune 
system to non-pathogenic and self-antigens [282]. Accordingly, Shimomura et 
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al. studied the influence of housing mice in CV and SPF facilities on the 
regulatory function exerted by B-1 B cells in chronic colitis. They found that 
maintaining mice in CV facilities suppressed colitis compared to mice 
maintained in SPF facilities, and that this protection from colitis was dependent 
on the presence of B cells as B cell deficient mice continued to develop colitis 
even in the CV facilities [274]. 
In line with Shimomura et al. I found that T2-MZP and T1 B cells obtained from 
mice kept in the CV facility were able not only to suppress TNF-α expression by 
CD3/CD28 bead and allo-DCs activated CD4+ T cells in vitro (Figure 3.5), but 
also to significantly prolong B6-Kd skin graft survival on B6 recipients 
maintained in CV facility (Figure 3.14 B). These results suggest the possibility 
that cells separated from mice in CV facility have been primed and educated in 
vivo to exert the immune regulatory functions required. However, how T2-MZP 
and T1 B cell interactions with microorganisms have driven these cells to 
become regulatory is still to be investigated.  
One possibility to explain the effect that housing mice in CV facilities has on the 
function of regulatory B cells is that microorganisms can activate B cells directly 
via their TLRs. Signals provided by microbes might be essential for the 
development and effector functions of T2-MZP and T1 B cells. It has been 
reported that TLR ligation on B cells can directly stimulate and mediate B cells 
to produce cytokines and antibodies [283]. Apoptotic cells (ACs) express TLR-9 
ligands and can down-regulation inflammation caused by the innate immune 
cells [284,285,286,287,288] and protect mice from inflammation induced during 
autoimmune diseases [289]. A recent report has shown that stimulating B cells 
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with ACs induces B cells to produce IL-10 [264]. Additionally, the report 
documented that B cells isolated from mice whose B cells lack the expression of 
TLR-9 failed to produce IL-10 upon ACs stimulation [264]. This study further 
supports the important role that TLRs play in B cell responses. However, to 
confirm this possibility further work is required. For instance, keeping mice 
expressing MyD88-/- B cells in CV facility, and examine whether MyD88-/-B cells 
in particular T1 and T2-MZP can provide the same suppressive role in vitro and 
in vivo as WT T1 and T2-MZP B cells.  
The results in this chapter have also shown that T2-MZP and T1 B cells isolated 
from mice kept in CV, SPF facilities, or Gal-1-/- mice maintained in CV facility 
expressed similar levels of IL-10, but only B cells isolated from those mice 
housed in CV facility showed regulatory effect in vitro (inhibiting TNF-α 
expressing CD4+ T cells) and in vivo (prolonging allograft survival). Moreover, 
although MZ B cells expressed the highest level of IL-10 compared to other 
subsets obtained from mice kept in SPF, CV, or Gal-1-/- housed in CV facilities, 
they exhibited little to no regulatory function in vivo or in vitro. Additionally, pre-
activating B cell subsets in vitro to express higher levels of IL-10 failed to drive 
T1 or T2-MZP B cell regulatory function (Figure 3.4). These results suggest that 
IL-10 might not be the major mechanism involved in T2-MZP and T1 B cells 
regulatory function. This is in contrast with what has been documented in 
autoimmunity where it has been found that T2-MZP B cell function in a contact-
independent and IL-10 dependent manner [146]. My results also disagree with 
a recent report in the field of transplantation, where anti-Tim-1 treated JHD mice 
(B cell deficient mice) showed earlier allograft rejection, however, re-constituting 
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the mice with WT B cells, but not IL-10-/- B cells, prolonged the allograft survival, 
indicating that IL-10 plays a key role in the regulatory function of B cells in that 
model [173]. However, it has also been reported that inducing tolerance to 
cardiac transplant in mice using anti-CD45RB monotherapy is B cell dependent 
and that IL-10 production by B cells was in fact counter-regulatory and IL-10 
neutralization improved graft outcome [318]. One can only postulate that B cells 
provide their regulatory function through different mechanisms according to the 
model and how B cells have been primed. To confirm the IL-10 hypothesis, IL-
10-/- mice might be helpful to verify that IL-10 is not the major player in the 
model presented in this thesis. However, housing IL-10-/- mice in CV facilities 
would cause severe inflammation in the mice making it difficult to use them for 
these experiments. 
Studies have shown that Gal-1 plays a key role in B cell function, in terms of 
immunoglobulin production [205], development [206], and their influence on T 
cells [207]. In addition Gal-1 has been discovered as a	  molecule involved in 
Treg suppressive function [196]. Therefore, I investigated whether Gal-1 was 
involved in T2-MZP and T1 B cell regulatory function. First, I confirmed by using 
western blot that B cells isolated from spleens of B6 mice expressed Gal-1 
(Figure 3.8). This result is in agreement with the published work of Zuniga et al. 
in which demonstrated that B cells express Gal-1 [207]. Since this experiment 
required at least 0.5-1 million of cells after collection and washing, my attempt 
to examine Gal-1 expression in B cell subsets failed due to the low numbers of 
cells obtained after purifying the B cell subsets.  
Next, I demonstrated that Gal-1-/- T2-MZP and T1 B cells lack suppressive 
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capacity (Figure 3.9). Moreover, the adoptive transfer of wild type T2-MZP B 
cells prolonged MHC I mismatched skin grafts significantly compared to PBS 
controls or mice that received Gal-1-/- T2-MZP B cells. Mice that received Gal-1-
/- T2-MZP B cells rejected their graft even earlier than the controls (Figure 3.14 
C). The results were similar when the effect of Gal-1 on the capacity of T1 B 
cells to prolong graft survival were investigated. However, the difference in skin 
survival between mice that received WT T1 B cells and Gal-1-/- T1 B cells was 
not significant, and a few additional experiments may be required to reach a 
significant difference (Figure 3.14 C). These results suggest that the expression 
of Gal-1 is essential for T2-MZP, and probably T1, B cell regulatory function. 
Thus, the role of Gal-1 as a functional regulatory molecule for Tregs was 
extended in this study to B cells [196]. However, the mechanism behind the 
regulatory role of Gal-1 during transplantation remains to be investigated.  
As previously reported Gal-1 plays an important role in B cell development by 
anchoring the interaction between stromal cells integrins and pre-BCR on B 
cells providing survival signals during their development [208]. This might 
indicate that the observed functional defect in T2-MZP and T1 B cells in the 
transplant model presented here may be due to the altered interaction times or 
interaction kinetics between BM stromal cells and pre-B cells during B cell 
development in Gal-1-/- mice that might resulted in the generation of 
dysfunctional B cells. This might also explain the significant increase in the 
percentage of T2-MZP B cells in Gal-1-/- mice compared to WT mice (Figure 
4.1). The loss of regulatory capacity by Gal-1-/- B cells might also be due to the 
requirement for Gal-1 in B cell intracellular signaling pathways (this point is 
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addressed in the next chapter in more detail). Exogenous Gal-1 has previously 
been reported to have an inhibitory effect on NF-κB activation in T cells, in 
particular Th1 T cells [266]. In addition, It has been documented that Gal-1 can 
interact with Ras at the cell membrane and activate the ERK pathway [187]. 
Another possible mechanism is that Gal-1 production by T2-MZP B cells is 
essential in shifting T cell responses from Th1 and Th17 to Th2. Toscano et al. 
have shown that Th1 and Th17, but not Th2, express on their surface a set of 
glycans that trigger cell death signal upon binding to Gal-1 [203]. Also, it has 
been reported that Gal-1 secreted by Th2 cells induced selective apoptosis of 
Th1, whereas Gal-1 produced by Th1 mediate secretion of Th2 cytokines [202].	  
Thus, the lack of regulatory function displayed by Gal-1-/- T2-MPZ B cells may 
be a result of their inability to secrete Gal-1 to directly inhibit T cells. 
I attempted to block extracellular Gal-1 during the co-culture of allo-DCs, CD4+ 
T cells and B cell subsets by using lactose. However, adding lactose to the 
control culture containing allo-DCs and TNF-α expressing CD4+ T cells lead to 
a decrease in the percentage of TNF-α expressing CD4+ T cells compared to a 
culture under the same conditions but without lactose. This result suggests that 
the presence of lactose in culture interfered with the interaction of T cells and 
allo-DCs. 
Several co-stimulatory molecules on the surface of B cells have been identified 
to be up-regulated upon B cell activation, such as the B7 family molecules 
(CD80/CD86), CD40, ICAM-1, LFA-1 and VCAM-1 [291,281]. CD80 and CD86 
molecules are of the best defined among these molecules, and it is well 
documented that their engagement with CD28 on T cells plays an important role 
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in T cell proliferation, cytokine production and their development to effector 
cells. On the other hand, it has been recently reported that CD80 and CD86 are 
essential for inhibiting and enhancing B cell activities, respectively [291]. In the 
present study, I have investigated the possible role of B7 molecules in B cell 
subsets regulatory function. Here, CD3/CD28 bead activated TNF-α expressing 
CD4+ T cells were co-cultured with WT B cell subsets with or without anti-CD80 
and anti-CD86 neutralizing antibodies. The results showed that by neutralizing 
B7 molecules T2-MZP B cells significantly loss their suppressive capability 
compared to controls (Figure 3.10 A). These results point to the important role 
of B7 molecules in T2-MZP B cells regulatory function. This experiment was in 
the absence of any type of APC because the neutralizing anti-B7 mAb inhibited 
allo-DCs activated TNF-α expressing CD4+T cells.  
Another mechanism that I have investigated in this chapter is the involvement of 
alloantibody to graft rejection. Alloantibodies have been known for their central 
role in provoking transplant rejection through complement-dependent and 
complement-independent pathways [63]. Here, allo-IgGs were measured in 
sera collected (one month after transplant) from mice kept either in SPF or CV 
facilities either received no B cells or received adoptive transfers of B cell 
subsets. Figure 3.13 & 3.14 showed no correlation between allo-IgG and graft 
rejection, and both groups of mice (SPF vs. CV) produced allo-IgG. These 
results suggest that the presence of allo-IgG does not correlate with T2-MZP B 
cells ability to prolong skin survival.  
In this chapter, I have also found that MZ B cells expressed the highest level of 
IL-10 and were capable of suppressing TNF-α expressing CD4+ T only when T 
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cells were activated with beads, but not with allo-DCs. Furthermore, their 
adoptive transfer significantly prolonged MHC I mismatched skin graft survival. 
However, transfer of T2-MZP B cells provided a significantly better survival rate 
than MZ B cells, and the prolongation provided by MZ B cells, although 
significant, was not very different from the controls.  
T1 B cells were also able to suppress and there are a number of possible 
reasons to explain these findings. First, T1 B cells are very immature cells, and 
it is possible that once injected or stimulated they mature into T2-MZP B cells. 
However, this hypothesis needs to be investigated further. Secondly, it could be 
related to their survival capacity. T1 B cells do not survive very well through the 
process of isolation and FACS sorting, so it maybe that the cells injected are in 
fact apoptotic, and, as described above, apoptotic cells can possess an 
immune-regulatory function. Further investigation could clarify this point, such 
as labeling the cells with CFSE to monitor their survival, or by phenotyping the 
cells again after in vivo injection or culture. 
The fact that T2-MZP and T1 B cells function differently simply as a result of 
housing the mice in the two facilities where the major difference is the level of 
sterility, lead me to investigate their immunological make up, their responses to 
stimuli ex vivo and their gut microbiota colonization. 
As previously reported gut microbiota can shape the immune system by 
strengthening the cooperation between adaptive and innate immune systems, 
so they establish strong gut barrier and prevent the microbiota from invading 
the host [292]. Also, it has been documented that alteration in the gut 
microbiota during childhood modulates the development of the immune system 
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[293,294]. Moreover, immune cells continually recognize microbial antigens via 
their TLRs, which initiate complex interactions between microbiota and the 
immune cells [295]. These interactions have been reported to shape immunity 
throughout life [296,297]. Therefore, I next sought to determine if housing the 
mice under different hygienic conditions (CV vs. SPF) could effect the gut 
microbiota composition. Here, I found that mice housed in CV facility had a 
different composition of gut microbiota than mice kept in SPF facilities (Figure 
3.19 A). These results were associated with a significant increase in lymph 
node memory CD4+ and CD8+ T cells in mice kept in CV facility compared to 
SPF facility (Figure 3.15 E), indicating more productive immune responses in 
mice kept in CV facility. Furthermore, re-stimulating splenocytes isolated from 
mice housed in SPF facility showed that B cells expressed significantly higher 
levels of TNF-α and IFN-γ compared to B cells isolated from CV housed mice, 
and significantly higher level of IL-10 expressing CD4+ T cells in CV housed 
mice compared to mice kept in SPF facility (Figure 3.18). These data suggest 
that B cells from mice housed in CV facility tended to shift the Th1/Th2 balance 
toward Th2 compared to B cells from SPF facility. Also, I found that the 
percentages of GC B cells are significantly higher in the PPs and spleens of 
mice maintained in CV facility compared to mice kept in SPF facility (Figure 
3.19 B), further suggesting the higher state of activation of B cells in the gut 
when derived from mice kept in the CV compared to the SPF facility. Moreover, 
B cells in the lymph nodes isolated from mice kept in CV facility expressed 
significantly higher levels of MHC I and MHC II molecules compared to SPF 
facility (Figure 3.16 D). However, the housing conditions did not influence B cell 
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development (Figure 3.15 A). These results are in line with a recent study 
investigating the influence of microbial colonization on B cell development and 
function that investigated mice kept in germ free and CV facilities [280]. The 
authors reported that the differences in gut microbiota had no effect on B cell 
development. B cells isolated from the spleens and PPs of mice kept in CV 
facilities secreted higher levels of Ig however, suggesting that microbiota has an 
impact on B cells function [280]. 
Collectively, the results in this chapter showed that the level of sterility in which 
the mice are kept influences gut microbial homeostasis resulting in more 
productive immune responses. Furthermore, B cells from mice housed in CV 
facility acquired regulatory function allowing them to suppress TNF-
α expressing CD4+ T cells in vitro and to prolong allograft skin survival in vivo. 
Whether B cells can “acquire” regulatory function in other ways such as during 
transplantation tolerance induction, as suggested from work using blood from 
transplanted renal patients that become tolerant to the graft [56], will be 
addressed in Chapter 5. Finally, Gal-1 expression was necessary for the 
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Chapter 4 
In the previous chapter I have shown that B cell subsets, apart from FO B cells, 
can have regulatory function and prolong transplant survival but only when 
isolated from mice housed under non-hygienic conditions. These findings were 
associated with a difference in the hemostasis between gut microbiota of mice 
kept in SPF and CV facilities. This imbalance in gut microbiota suggested a 
possible role for TLR signaling that might educated the B cells in vivo to exhibit 
their regulatory function. Signaling via TLR molecules has been shown to play 
an important role in modifying the responses of B cells, such as their cytokine 
secretion, antibody production and their capacity to present antigen [251]. 
Cytokine secretion by B cells upon TLRs ligation can influence Th cells 
polymerization at early stage. In Salmonella enterica model, B cell activation 
through TLRs without antigen requirement were essential for Th1 generation, 
while antigen presentation and BCR were important for Th1 memory formation. 
Infecting MyD88-/- mice with S.enterica, and re-stimulating purified B cells from 
this mice with heat-killed bacteria showed negligible secretion of IL-6, IL-10 and 
IFN-γ, suggesting complete dependency on TLRs signaling in B cells to secrete 
those cytokines [263]. Moreover, Miles et al, found that apoptotic cells (AC), 
which express chromatin complex and stimulate TLR-9, when treated with 
DNase and adoptively transferred did not protect the mice from arthritis 
compared to the controls that received non-treated AC. Moreover, in TLR-9-/- 
mice AC-administration did not mediate protection from EAE [264]. Re-
stimulation of splenocytes isolated from TLR-9-/- mice with EAE at day 12 
showed a significant drop in IL-10 and higher levels of IL-17 and IL-6 compared 
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to WT mice. Moreover, protection from EAE by AC was restored by the adoptive 
transfer of WT B cells together with AC, but not when B cells were coming from 
TLR-9-/- mice, suggesting that TLR-9 is essential for B cells to maintain self-
tolerance in heath [264].  
The engagement of TLRs triggers various signaling pathways leading to the up-
regulation of co-stimulatory molecules and cytokine production [217,229]. Co-
stimulatory molecules shape B cell responses and their functions in the immune 
system. For example, antigen specific B cells can be very potent antigen 
presenting cells by presenting antigens in a specific manner via their MCH I and 
II to both CD4 and CD8 T cells [126,127,128]. Therefore, B cells have the ability 
to shape the level of T cell responses [260,275,126,127]. Cytokine production 
by B cells contributes as well to the development of the lymphoid 
microenvironments [298], and in shaping T cell responses [275,276,277]. For 
example, IL-10 secretion by B cells can down regulate inflammation associated 
with autoimmune diseases via modulating T cell function [145,146,149,169].  
Finally, I have shown in Chapter 3 that the expression of Gal-1 is essential for B 
cell regulatory function and that B cells that lack Gal-1 expression from mice in 
CV conditions cannot inhibit the immune responses both in vitro and in vivo. 
Gal-1 has already been reported to play a key role in B cells development [208]; 
Abs production [205] and Gal-1 producing B cells can regulate T cell responses 
[207].  
Bringing all these results together, I addressed in this chapter the consequence 
of TLR-4 and TLR-9 ligation on B cell functions with particular attention to co-
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stimulatory molecules expression and the production of the immunoregulatory 
cytokine IL-10.  
 
Note: all the cells and tissues in this chapter have been obtained from the SPF 
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4.1 B cell proportions in Gal-1-/- mice. 	  
As I have previously shown in chapter 3 that B cells express Gal-1. In this 
chapter I investigated the consequence for B cell stimulated by TLRs of lack of 
Gal-1-expression. However, first I evaluated the proportions of B cells and their 
development in WT and Gal-1-/- mice. I isolated spleens, lymph nodes and PPs 
from Gal-1-/- mice and WT mice and compared the percentages of T2-MZP, T1, 
MZ, FO and GC B by flow cytometry. I found significantly higher percentage of 
T2-MZP B cells, as a proportion of total B cells, in the spleens of Gal-1-/- 
compared to WT mice, whereas there were a lower percentage of GC B cells in 
the spleens of Gal-1-/- mice compared to WT mice (Figure 4.1 A, B and C). In 
contrast, WT and Gal-1-/- mice have the same percentages of B cells and B cell 
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4.2 Gal-1-/- B cells express significantly higher levels of 
co-stimulatory molecules compared to WT B cells in 
response to LPS. 	  
Co-stimulatory molecules are key in contributing to the immune response. It is 
known that antigen-specific B cells are very potent antigen presenting cells 
(APC) by concentrating antigens via their BCR and presenting them on their 
MHC class I and class II to CD8+ and CD4+ T cells, respectively 
[125,126,127,128]. B cells can provide additional signals for the activation and 
proliferation of T cells through CD80 and CD86 [135,136]. Therefore,	   I next 
examined whether Gal-1 expressed by B cell can contribute to co-stimulatory 
molecule expression following TLR stimulation. Here, I isolated B cells 
magnetically, and activated them with the following stimuli: LPS, CPG, anti-
CD40, LPS/CPG, anti-CD40/LPS and anti-CD40/CPG for 48hrs. Subsequently, 
CD80, CD86, CD40 and MHC II expression were measured by flow cytometry. 
The results showed first of all that resting naïve Gal-1-/- B cells expressed 
similar levels of MHC and co-stimulatory molecules to WT B cells, with the 
exception of MHC I, which was expressed at lower levels on Gal-1-/- B cells 
(Figure 4.2). Following LPS stimulation however Gal-1-/- B cells expressed 
significantly higher levels of CD80, CD86, CD40 and MHC II compared to WT B 
cells. Gal-1-/- B cells expressed higher levels of CD86 and MHC II following 
stimulation with LPS. CD80 molecules were also expressed at higher levels 
when B cells from Gal-1-/- mice were stimulated with LPS and LPS plus anti-
CD40 mAbs compared to WT B cells. Finally, CD40 molecules were also 
expressed at higher levels on B cells isolated from Gal-1-/- mice compared to 
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those isolated from WT mice following stimulation with anti-CD40, anti-
CD40/LPS and anti-CD40/CPG (Figure 4.3). 
These results suggest that Gal-1 might have a role in negatively regulating the 
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4.3 B cells isolated from the Peyer’s Patches of Gal-1-/- 
mice express higher levels of CD80 and CD86 
compared to WT B cells. 	  
Given that Gal-1-/- B cells expressed higher levels of CD80 and CD86 than WT 
B cells following stimulation in vitro with LPS I investigated whether B cells 
recovered from sites of activation in vivo had the same phenotype of the B cells 
activated in vitro. In this experiment, I compared the expression of CD80 and 
CD86 molecules by WT and Gal-1-/- B cells isolated from PPs as these sites 
should contain B cells continuously activated by gut antigens and via their 
TLRs. In agreement with the in vitro results Gal-1-/- GC B cells expressed 
significantly higher levels of CD80 and a tendency to express higher levels of 
CD86 molecules (Figure 4.4) 
To summarize Gal-1-/- B cells expressed higher levels of co-stimulatory 
molecules compared to WT B cells in vitro (LPS) and when obtained ex vivo. 
These results suggest that stimulation of B cells via TLR-4 ligand (LPS) in the 
absence of Gal-1 might results in a higher level of B cell activation.  
 
 
 	  	   	  	  	  	  
	  
	  	  	  	  	  	  	  	  	  Figure	  4.4	  Gal-­‐1-­‐/-­‐	  B	  cells	  express	  higher	  levels	  of	  CD80	  and	  CD86	  compared	  to	  WT	  B	  cells,	  Ex	  vivo.	  
	   149	  






























































	   150	  
4.4 Different amount of IL-10 produced by Gal-1-/- B 
cells compared to WT B cells in response to CPG when 
two detection assays were used. 	  
Cytokine production by B cells is an important mechanism in the development 
of lymphoid tissue microenvironments [298], and shaping T cell responses 
[275,276,277]. For example, IL-10 secretion by B cells can down regulate 
inflammation associated with autoimmune diseases via modulating T cell 
functions [145,146,149,169]. In addition, it has been reported that the adoptive 
transfer of a subset of B cells (T2-MZP) were capable of protecting from 
autoimmune diseases through IL-10 production [146,149]. Since I was 
interested in the suppressive role of B cells, which has been reported to be 
dependent on IL-10, I next determined if Gal-1 deficiency would have affected B 
cell capacity to produce IL-10. B cells were isolated magnetically from Gal-1-/- 
and B6 mice, and cultured with combinations of different stimuli, LPS, CpG and 
anti-CD40 for 48hrs. PMA and Ionomycin and brefeldin A were added for the 
final 4 hrs of culture after collecting supernatants for ELISA. The intracellular 
staining results in figures 4.5 A & B show that IL-10 expression was significantly 
lower in Gal-1-/- B cells at 48hrs compared to WT B cells in particular following 
stimulation with TLR-9 ligand CPG. However, the ELISA results in figure 4.5 C 
show that after ~48hrs Gal-1-/- B cells had tendency to secrete higher levels of 
IL-10 compared to WT B cells with most of the stimuli. The ELISA results were 
confirmed by using cytokine bead array. The cytokine bead array results 
demonstrated that Gal-1-/- B cells secreted significantly higher levels of IL-10 
compared to WT B cells after ~48hrs of stimulation with CPG and LPS (Figure 
4.5 D). 
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Given that intracellular staining provides a snapshot of what the cells are 
expressing at certain time points, while ELISA detects the cumulative cytokines 
produced over the culture period, the different results obtained with the two 
methods suggest that there is a difference in the kinetic of IL-10 production by 
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4.5 Gal-1-/- B cells exhibit different kinetics than WT B 
cells. 	  
To investigate the hypothesis that Gal-1-/- B cells produced IL-10 with different 
kinetics to WT B cells, Gal-1-/- and WT B cells were cultured with combinations 
of LPS, CpG and anti-CD40 for 6, 24 and 48hrs. PMA and Ionomycin and 
brefeldin A were added for the final 4hrs of culture after collecting supernatants 
for ELISA. Intracellular staining showed a significant increase in IL-10 
expression by Gal-1-/- B cells at 6hrs (Figure 4.6 A & B), and a trend of higher 
expression at 24hrs (Figure 4.6 C). However, a significant drop in IL-10 
expression by Gal-1-/- B cells was observed at 48hrs particularly with CPG, 
compared to WT B cells (Figure 4.6 D). These results were also confirmed in 
ELISA, where Gal-1-/- B cells had a tendency of producing higher levels of IL-10 
at 6 and 24hrs (Figure 4.7 A and B). Although I observed a higher level of IL-10 
at 48hrs in the supernatants of Gal-1-/- B cells compared to WT B cells (Figure 
4.7 C), the intracellular staining has demonstrated that Gal-1-/- B cells stopped 
expressing IL-10 at this time point. The differences in kinetics of IL-10 
production between WT and Gal-1-/- B cells were not a result of differences in 
the viability of the B cells (Figure 4.8). FACS staining with live/dead fixable blue 
dead cell stain kit revealed no significant differences between Gal-1-/- and WT B 
cells at any time point or in the presence of any of the stimuli. 
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4.6 Alterations in IL-10 expression by Gal-1-/- B cells 
compared to WT B cells following TLR-9 ligation 
appear to be localized particularly to T2-MZP & FO B 
cell subsets. 	  
To identify which B cell subset is the most affected by Gal-1 deficiency, I looked 
at the expression of IL-10 by FACS purified B cell subsets following TLR 
stimulation. B cells were magnetically isolated from B6 and Gal-1-/- mice, and 
subsets were purified by flow cytometry. Cells were then cultured with 
combinations of LPS, CpG and anti-CD40 for 48hrs. PMA and Ionomycin and 
brefeldin A were added for the final 4hrs of culture after collecting supernatants 
for ELISA. Figures 4.9 A, B and C show that the same significant drop in IL-10 
expression observed with total B cells was seen with T2-MZP and FO B cells, 
particularly with CPG stimulation. In figure 4.9 D is shown that IL-10 expression 
by T1 was also slightly decreased with most stimuli, however the differences 
were not significant and could be explained by the high degree of cell death by 
both WT and Gal-1-/- T1 B cells. There were no differences in IL-10 expression 
by MZ B cells isolated from Gal-1-/- or B6 mice (Figure 4.9 E). 
The ELISA results in figure 4.10 show that over the course of 48hrs both WT 
and Gal-1-/- T2-MZP and FO B cells have secreted similar amounts of IL-10 
even though Gal-1-/- T2-MZP and FO B cells have significantly reduced IL-10 
expression (ICC) by this point. 
These results suggest that Gal-1 deficiency affects T2-MZP and FO B cell IL-10 
production more than T1 or MZ B cells.  
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4.7 Gal-1-/- B cells express the same level of TLRs and 
have the same capacity to uptake LPS as WT B cells. 	  
To exclude the possibility that the functional differences between Gal-1-/- and 
WT B cells were simply due to reductions in the expression of TLR-4 and TLR-9 
by Gal-1-/- B cells compared to WT B cells, I examined the expression of these 
two TLRs on Gal-1-/- and WT B cells. B cells were magnetically isolated, 
activated with combinations of LPS, CpG and anti-CD40 for 48hrs, and stained 
with anti-CD19, anti-TLR-4 and anti-TLR-9 antibodies (ICC). I found no 
differences in TLR-4 and TLR-9 expression between Gal-1-/- and WT B cells 
apart from a slightly reduced expression of TLR-4 following LPS stimulation in B 
cells from Gal-1-/- mice (Figure 4.11). 
In view of the fact that Gal-1 is a carbohydrate-binding protein, and LPS is 
mainly lipid and carbohydrate [187,299], I tested whether the absence of 
extracellular Gal-1 influenced LPS uptake by Gal-1-/- B cells. B cells isolated 
from Gal-1-/- and B6 mice were incubated with LPS labeled with FITC and anti-
CD19 Abs for 30 minutes, washed, and then FITC expression by CD19 B cells 
was evaluated by flow cytometry. The results showed no significant differences 
in LPS uptake between Gal-1-/- and WT B cells (Figure 4.12 B). 
In summary, I did not observe marked differences in TLR expression, or in the 
level of LPS uptake, between Gal-1-/- and WT B cells, suggesting that Gal-1 
deficiency may be affecting B cell signaling via TLRs agonists intracellularly.  
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4.8 Gal-1-/- B cells showed significant decrease in P38 
phosphorylation but an increase in ERK 
phosphorylation in response to CPG, but not LPS. 	  
The engagement of TLRs triggers various signaling pathways leading to the up-
regulation of co-stimulatory molecules and cytokine production [217,229]. The 
results presented in this chapter so far have suggested that Gal-1 deficiency 
altered TLR-4 mediated signaling in B cells resulting in up-regulation of co-
stimulatory molecules. Whereas, the engagement of TLR-9 with CPG in the 
absence of Gal-1 alters intracellular signaling in such a way that the kinetics of 
cytokines production, and in particular IL-10 production, are affected.  
It has been reported that the phosphorylation of P38 and ERK, and the 
translocation of NF-κB are necessary steps in the signaling pathways leading to 
IL-10 production [300]. Therefore, I sought to determine whether Gal-1 
deficiency altered intracellular signaling downstream of TLR-4 and TLR-9 by 
investigating the effect of TLR-ligation on P38, ERK and NF-κB molecules. 
To investigate the effect of Gal-1 deficiency on intracellular signaling molecules, 
B cells were magnetically isolated and stimulated with CPG or LPS for 0, 10, 
30, 45 and 60 minutes. Cells were then fixed and stained with anti-CD19, and 
then intracellularly with anti-phosphorylated p38 or anti-pERK antibodies. As a 
positive control for p38 and ERK phosphorylation, B cells were activated with 
PMA and ionomycin at each time point.  
Gal-1-/- B cells showed a significant decrease in the percentage of cells with p38 
phosphorylation compared to the WT B cells at later time points (60mins) 
(Figure 4.13). While stimulating B cells with LPS resulted in a slight increase in 
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the percentage of p38 phosphorylation in Gal-1-/- B cells compared to the WT B 
cells, in particular at the early stages of activation (10 and 30mins), but the 
difference was not significant (Figure 4.14). 
CPG activated Gal-1-/- B cells, in contrast, showed a significantly higher 
percentage of ERK1/2 phosphorylation than WT B cells at 60 minutes (Figure 
4.15). In contrast, no differences in the percentage of ERK1/2 phosphorylation 
between Gal-1-/- and WT B cells were observed when they were activated with 
LPS (Figure 4.16). 
These results suggest that Gal-1 might act as positive regulator for P38 
phosphorylation upon TLR-9 ligation, but not TLR-4. These results also suggest 
that Gal-1 might act as negative regulator for ERK phosphorylation upon TLR-9 
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4.9 Gal-1-/- B cells exhibit a significant decrease in NF-
κB translocation in response to both LPS and CPG. 	  
In order to investigate whether Gal-1 deficiency altered NF-κB translocation, B 
cells were isolated by magnetic sorting, and activated with CPG and LPS for 0, 
20, 45 and 90 minutes. Next, cells were fixed and stained with DAPI for nuclear 
staining and anti-NF-κB (Figure 4.17 A). Cells were then analyzed using the 
ImageStream flow cytometer/microscope system. The results in figure 4.17 
show a significant drop in the percentage of NF-κB translocation in Gal-1-/- B 
cells compared to WT B cells following both LPS and CPG. 
Collectively, the results obtained from the analysis of the signaling molecules 
suggest that Gal-1 might play an important role in shaping TLRs mediated 
signaling pathways supporting NF-κB translocation when B cells are activated 
through TLR-4 and 9, up-regulating P38 (TLR-9) and down-regulating ERK 
(TLR-9) with no influence observed on P38 and ERK in response to LPS. The 
alteration in the signaling pathways either affected the expression of co-
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Discussion 	  
Gal-1 has been known as an immunoregulatory molecule that can regulate 
many cellular functions, and as an essential molecule for Treg regulatory 
function [187,190,191,196]. Recently, it has also been identified as a key 
molecule in several B cell functions [208,205,207]. In this chapter, I addressed 
the role of Gal-1 in B cell activation when B cells were stimulated by TLR-4 and 
9 agonists, TLRs which are also known to be important in B cell responses 
[251]. Looking at the expression of co-stimulatory molecules and cytokine 
production by B cells isolated from WT and Gal-1 deficient mice, I found that 
Gal-1-/- B cells behaved differently than WT B cells. Briefly, when stimulated 
with CPG, Gal-1-/- B cells expressed significantly lower levels of IL-10, and 
exhibited a significant drop in NF-κB translocation and P38 phosphorylation with 
a significant increase in ERK phosphorylation compared to the WT B cells. 
Whereas Gal-1-/- B cells, when stimulated with LPS, expressed significantly 
higher levels of co-stimulatory molecules and produced significant higher 
amount of IL-10 compared to WT B cells and this was associated with a 
significant decrease in NF-κB translocation and no effect on P38 or ERK 
phosphorylation when compared to WT B cells. 
It has previously been reported that Gal-1 has a key role in B cell development 
by anchoring the interaction between stromal cells, integrins, and the pre-BCR 
on B cells providing survival signals during their development [208]. In line with 
this report our results in figure 4.1B show that splenic B cell subsets isolated 
from Gal-1-/- mice have a significant increase in the percentage of T2-MZP B 
cells compared to the controls (WT B cells). This result suggests the possibility 
	   172	  
that B cells might get trapped at this stage of development due to the absences 
of Gal-1.  
Next, I examined whether the absence of Gal-1 expression by B cells affected 
the responses to TLR-4 and 9 stimuli. The expression of co-stimulatory 
molecules and cytokine production by B cells were analyzed. Gal-1 has been 
reported as a strong enhancer of IL-10 production, as activating PBMC with 
anti-CD3 antibody in the presence of Gal-1 increased IL-10 production 
compared to controls [204]. In addition, it has been documented that stimulating 
human monocyte-derived DCs cells with Gal-1 induces cell maturation and the 
up-regulation of CD40, CD86 and HLA-DR [301]. In the present chapter I found 
that Gal-1-/- B cells showed a significant increase in CD80, CD86, CD40 and 
MHC class-II molecules expressions in response to LPS, but not CPG, 
compared to WT B cells (Figure 4.3). In agreement with our in vitro results, GC 
B cells expressed significantly higher levels of CD80 molecules when isolated 
from Gal-1-/- mice compared to controls, and tended to express higher levels of 
CD86 molecules (Figure 4.4). CD80 and CD86 were selected in this experiment 
due to the low numbers of cells obtained from the PPs. Also, it has been 
previously reported that the expression of these two molecules on B cells 
provides essential signals for the activation and proliferation of CD4+ T cells 
[136]. CD80 and CD86 are also important for inhibiting and enhancing B cell 
proliferation and IgG production, respectively [291]. Collectively, these results 
suggest that stimulation of B cells via TLR-4 ligand in the absence of Gal-1 
might results in a higher level of activation and will alter the strength of 
interactions with T cells via their CD80, CD86, CD40 and MHC II molecules. 
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On the other hand, Gal-1-/- B cells in response to CPG in vitro, showed no 
differences in their co-stimulatory molecule expression compared to controls, 
but their cytokine expression and production were significantly different 
compared to controls (Figure 4.6 & 4.7). Gal-1-/- B cells have expressed IL-10 in 
significantly higher levels than WT B cells at early time points post activation 
(Figure 4.6 B & C), however, this sharp increase was followed by a significant 
drop at 48 hours post stimulation (Figure 4.6 D). Suggesting that Gal-1 
deficiency in B cells has accelerated the cell responses to CPG at early time 
points post activation to produce higher level of IL-10 which might have an 
autocrine affect by switching off IL-10 production at 48 hours post stimulation. In 
conclusion Gal-1 might act as an essential regulatory molecule for IL-10 
producing B cells. My data are in agreement with a previous report by Van der 
leji et al. in which they reported that stimulating PBMCs cells in the presence of 
Gal-1 enhanced IL-10 production by the cells compared to a culture without 
Gal-1 [302]  
Gal-1 has been reported to play an important role in shifting Th1/Th2 balance 
toward Th2 by inducing Th1 apoptosis [202,203]. Since Gal-1 has documented 
to regulate T cell survival, I examined under the same conditions of activation 
whether the absence of Gal-1 in B cells could affect their survival. As figure 4.8 
shows Gal-1 deficiency did not influence B cell survival, suggesting that the 
results seen with IL-10 in Gal-1-/- B cells were not due to the viability of the cells. 
My data are in agreement with the previous report by Zuniga et al. in which they 
reported that Gal-1 produced by B cells activated with Trypanosoma cruzi 
induced T cell apoptosis, but did not affect B cell survival [207]. 
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To determine which B cell subsets were most affected by Gal-1 deficiency, B 
cell subsets were purified and activated with TLR-4 and 9 stimuli, and IL-10 
expression and production were measured. As with total B cells, Gal-1-/- T2-
MZP and Gal-1-/- FO B cells showed the same significant drop in IL-10 
expression compared to control (Figure 4.9). The data suggest that the drop 
seen in IL-10 production with total B cells from Gal-1-/- mice was due to the 
decrease in IL-10 observed in T2-MZP and FO B cell subsets.  
The engagement of TLRs is known to activate several signaling pathways that 
lead to the release of cytokines and the up-regulation of co-stimulatory 
molecules [217,229]. It has been reported that the phosphorylation of P38 and 
ERK, and NF-κB translocation are important for IL-10 production [300]. After 
excluding that any differences that I may have observed were due to different 
levels of TLRs expression (Figure 4.11) or capacity to uptake LPS (Figure 4.12), 
NF-κB translocation, P38 and ERK phosphorylation were examined in B cells 
isolated from Gal-1-/- and WT mice. Here, I found a significant drop in NF-κB 
translocation in Gal-1-/- B cells compared to WT B cells in response to both 
CPG and LPS (Figure 4.17). I also observed a significant decrease in P38 
phosphorylation in Gal-1-/- B cells in response to CPG, but not LPS (Figure 4.13 
& 4.14). In contrast, a significant increase in ERK phosphorylation in Gal-1-/- B 
cells compared to WT B cells in response to CPG was seen (Figure 4.15 & 
4.16). The results obtained after ligation of TLR-9 are in agreement with 
previous reports in which IL-10 production was associated with NF-κB down-
regulation and ERK up regulation [244-248], further supporting a role for Gal-1 
in regulating IL-10-production mediated by TLR-9 signalling. However, in the 
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case of TLR-4 ligation, the high IL-10 production was only correlated with the 
decrease in NF-κB translocation, but no obvious involvement of ERK or P38 
molecules.  
Altogether the findings in this chapter suggest that Gal-1 plays different 
regulatory roles in controlling IL-10 production by activated B cells depending 
on the TLR that has been stimulated. However, how Gal-1 provides this role 
and where Gal-1 is involved in these pathways need to be further investigated. 
For example, immunoprecipitation can clarify at which stage Gal-1 is involved. 
Moreover, GaL-1-/- B cells activated via TLR-4 showed up regulation in co-
stimulatory molecules. However, none of the signalling pathways that have 
been investigated in this chapter showed an association, suggesting the 
possibility that other pathways might be involved, such as JNK pathway. 
In summary, I have reported in this chapter for the first time that Gal-1 has an 
important role in B cell responses to TLR-4 and TLR-9, and that the absences 
of Gal-1 has affected B cells intracellular signalling pathways to up-regulate 
both their co-stimulatory molecules and IL-10 production in response to LPS, 
while affecting only IL-10 production in response to CPG. The findings in this 
part of my thesis contribute to the understanding of the central role that Gal-1 
plays in regulating B cells functions in response to TLR ligation. This builds on 
the results in chapter 3 were Gal-1 was found to play an essential role in the 
regulatory function of B cells.  
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Chapter 5 
There is growing evidence that B cells contribute to the maintenance of 
transplant tolerance [303,304], as well as promoting chronic allograft responses 
[305,306,307]. In mice, anti-CD20 depletion accelerates skin graft rejection 
[305], anti-CD45RB induced tolerance to heart transplants requires the 
presence of B cells [308], and resting B cells expressing donor antigen have 
been observed to indefinitely prolong heterotopic heart transplant survival [309]. 
In rats, long-term allograft tolerance is characterized by an accumulation of B 
cells expressing genes such as BANK-1 that are associated with tolerance 
[310].  
B cells have been primarily thought of as the source of alloantibodies that 
activate complement and varieties of effector cells, and mediate rejection [63]. 
For instance depletion of B cells with Rituximab in ABO incompatible renal 
transplant recipients has had positive results in delaying rejection [311,312]. 
However, the use of B cell depletion as induction therapy for some kidney 
transplant patients has lead to increased incidence of acute cellular rejection 
[60]. It is possible that in these cases B cell depletion is removing B cells that 
contribute to tolerance induction rather than those promoting rejection [61]. 
A “B cell signature” has been documented in spontaneously tolerant patients 
who received HLA mismatched kidneys and are not taking immunosuppreive 
agents. Genes associated with B cell function were up-regulated in PBMCs of 
tolerant patients compared to healthy controls and non-tolerant recipients [55]. 
In addition, the proportions of transitional B cells in the patients peripheral blood 
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were reported to be higher in drug free tolerant patients compared to healthy 
individuals and non-tolerant controls [56]. 
In this chapter a mouse model of skin transplant was used to investigate the 
tolerogenic role of B cells in transplantation. In line with the findings in humans, 
T2-MZP B cells were expanded in mice tolerised by donor splenocyte 
transfusion (DST) and anti-CD40L (MR1) treatment. Upon adoptive transfer, T2-
MZP B cells isolated from DST + MR1 treated mice were able to prolong skin 
graft survival in vivo and suppress TNF-α expressing T cells in vitro. Although in 
this model there was no evidence for T2-MPZ B cell IL-10 production, T2-MZP 
B cells isolated from DST + MR1 treated mice up-regulated TIM-1 expression 
but lose expression of CD86 suggesting an alteration in their T cell stimulatory 
capacity. 
Note all the experiments in this chapter were done in the SPF facilities of the 
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5.1 B cells are required for long-term tolerance to 
MHC I mismatched skin grafts in an experimental 
model of transplant tolerance. 	  
To investigate whether the B cells that are associated with transplant survival 
represent regulatory B cells that may contribute to the maintenance of tolerance 
we returned to a mouse model of experimental skin graft tolerance. Tolerance 
to skin grafts can be rendered in B6 mice receiving B6-Kd skin by pre-treatment 
with B6-Kd splenocytes and anti-CD40L antibody (MR1) [313]. Seven days 
before receiving a skin graft mice received 25x106 donor splenocytes (DST) + 
250 µg MR1 plus an additional injections of 100µg of MR1 three days before the 
graft, on the day of graft and four days subsequently. In order to determine 
whether the establishment of DST+ MR1 induced tolerance required B cells we 
attempted to induce tolerance in B cell deficient mice. Seven days prior to B6-Kd 
skin graft, B6 and µMt (B cells deficient) mice were treated with DST+MR1 
(Figure 5.1 A). Allografts survived indefinitely on B6 recipients. Although the 
treatment of µMt mice did prolong allograft survival compared to untreated and 
MR1 alone treated controls, tolerance was not seen in µMt mice treated with 
DST+MR1 (Figure 5.1 A). This result suggests that B cells play a role in 
maintaining tolerance to allograft. Interestingly, although the level of 
alloantibody was reduced in µMt mice treated with DST+MR1 compared to the 
controls, there was no correlation between graft rejection and alloantibody IgG 
production (Figure 5.1 B). Untreated mice produced detectable levels of anti-Kd 
antibody in their serum at one month after transplant. However, although most 
of the mice that received MR1 treatment alone had rejected the skin graft, none 
of the mice had detectable level of anti-Kd IgG antibody in their serum (Figure 
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5.1 B). CD40/CD40L interactions are essential for B cell class switching and 
generation of an antibody responses, it is possible that the MR1 treatment 
blocks this process [314]. Comparison of untreated and MR1 treated mice 
suggests that graft rejection of equal speed can occur in this model without the 
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5.2 T2-MZP and MZ B cells are transiently increased 
in tolerised mice. 	  
It has previously documented that B cells with T2-MZP phenotype have a 
regulatory role in mouse model of SLE and arthritis [146,149], MZ B cells in CIA 
[144], and B10 (CD5+ & CD1dhigh) B cells in EAE [168]. Therefore, we sought to 
determine if there were phenotypic changes in the B cell pool in tolerant mice 
compared to rejecting mice over the course of rejection. B6 mice were tolerised 
to B6 Kd skin grafts as above and spleens were recovered at day 9, 12, 15, 18 
and 21 mice after B6 Kd skin graft. Control mice received 25x106 B6 
splenocytes in order to allow for alterations in B cell numbers due to the DST in 
the tolerisation protocol. Subsequently, B cell subsets, B10 B cells and iNKT 
cells were phenotyped in the spleens obtained from each set. T2-MZP and MZ 
B cells showed significant increases as percentages of total splenic B cells in 
tolerised mice compared to rejecting mice at day 12 (Figure 5.2 A & B). B10 B 
cells showed a trend for an increase in tolerised mice compared to rejecting 
mice, however, this increase was not significant (Figure 5.2 E & F). FO and T1 
B cells showed no changes in their proportions (Figure 5.2 C and D). iNKT cells, 
also showed no differences in their percentage (Figure 5.2 G & H). 
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5.3 Adoptive transfer of T2-MZP B cells isolated from 
tolerised mice can prolong MHC I mismatched skin 
graft survival. 	  
Since T2-MPZ and MZ B cells displayed a significant increase in their 
proportions in the spleens of tolerant mice compared to controls, we examined 
their potential as immuneoregulatory cells in inducing transplant tolerance. 
Here, tolerance to B6 Kd skin grafts was induced in B6 mice as discussed in the 
previous section, B cell subsets were purified from splenic B cells of either 
tolerised or naïve B6 mice by FACS 14 days post transplant, and 1x106 cells of 
each subset were adoptively transferred (IV) into naïve B6 mice. One day 
subsequently the B6 mice received B6 Kd skin transplants. CD8 cells were 
depleted by IP injection of anti-CD8 antibody on day -1, 0 (day of skin graft), +1 
and every 7 days following the skin graft, and serums were collected 30days 
post transplant. In this model, T2-MZP B cells where the only subset to 
significantly prolong the skin survival (mean 19 days) compared to CD8 only 
controls (mean 15 days) or mice receiving any other B cell subset (means 12, 
15.5 and 15 days for T1, FO and MZ, respectively) (Figure 5.3 A). Consistent 
with my previous observation in chapter 3, T2-MZP B cells isolated from naïve 
B6 mice did not prolong allograft survival compared to the controls (Figure 5.3 
B). This suggest that T2-MZP B cells needs to be activated in vivo to exert their 
regulatory function. 
In line with the results in figure 5.1 there was no correlation between the levels 
of alloantibody and allograft rejection (Figure 5.3 C). Although T2-MZP B cells 
from tolerant mice prolong allograft survival and reduced the level of 
alloantibody, T1 and MZ B cells also showed low levels of alloantibody in their 
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serum even though they did not prolong skin survival following adoptive transfer 
(Figure 5.3 C). Suggesting that alloantibody production is not the driving force 
behind rejection in this model. 
It has been shown in autoimmune models that T2-MZP B cells are capable of 
suppressing TNF-α+ T cells in vitro. Therefore, we examine whether T2-MZP B 
cells isolated from tolerant B6 mice can exhibit the same affect in our model. In 
this experiment, B cells were isolated from the spleens of tolerised B6 mice by 
magnetic sorting. B cell subsets were then FACS sorted, and co-cultured with 
CD3/CD28 beads activated CD4+ T cells (1:1) isolated from mice that had 
rejected B6 Kd skin graft for 48 hours. PMA, Ionomycin and brefeldin A were 
added for the last 4 hours of culture. TNF-α was measured by intracellular 
staining and flow cytometry. The results showed that T2-MZP B cells were able 
to significantly suppress CD3/CD28 beads activated CD4+ T cells TNF-α 
expression by around 25% (Figure 5.4 A & B). In this model, no other B cell 
subset displayed a statistically significant inhibition of TNF-α expression by 
CD3/CD28 beads activated CD4+ T cells (Figure 5.4 A & B). 
In summary, only T2-MZP B cells prolonged skin survival in vivo and 
suppressed CD3/CD28 activated CD4+ T cell TNF-α expression in vitro when 
isolated from tolerised, but not naïve B6 mice. Moreover, alloantibody 
production seems not to be correlated with skin rejection in this model. 
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5.4 The suppressive capacity of T2-MZP B cells 
isolated from tolerant mice is not related to IL-10 or 
TIM-1 expression. 	  
In order to understand the possible mechanisms behind the ability of T2-MZP B 
cells isolated from tolerant mice to prolong allograft survival and suppress TNF-
α expressing CD4+ T cells in vitro we examined the expression of several 
molecules that have previously been reported to play a role in regulatory B cells 
function or B cells tolerance, such as IL-10, CD80/CD86, and TIM-1. 
IL-10 has been documented to play the major role in T2-MZP B cells regulatory 
function in autoimmunity [146,149]. Recently, in transplantation, it has been 
reported that TIM-1+ B cells have the capacity to prolong islet allograft survival 
post to their adoptive transfer [173]. Moreover, the expression of B7 molecules 
has been associated with B cells ability to suppress several autoimmune 
diseases [168]. Therefore, we examined whether the expression of any of these 
molecules could be involved in T2-MZP B cells suppressive capacity. 
To investigate the role of IL-10, B6 mice tolerised to B6 Kd skin and control non-
tolerised B6 mice were sacrificed at days 9, 12, 15, 18 and 21. Subsequently, B 
cells were magnetically isolated from the spleens of tolerant and control mice 
and sorted by FACS into subsets. The levels of IL-10 mRNA transcription by 
purified B cell subsets from tolerised mice were tested by RT-PCR and 
compared to the same subsets purified from naïve mice. There was a trend for 
IL-10 transcription to be up-regulated in T2-MZP B cells isolated from tolerant 
mice at day 15 post transplant, but this increase was not significant (Figure 5.5 
A). T1 B cells, which did not prolong skin allograft survival upon adoptive 
transfer, however did significantly upregulate IL-10 transcription over the course 
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of the study  (Figure 5.5 A). Furthermore, we investigated whether in vitro re-
stimulation of sorted T2-MZP B cells isolated from naïve and tolerised mice 
could highlight a difference in their IL-10 expression. Here, B cells were 
magnetically isolated from the spleens of tolerant and naïve B6 mice and sorted 
by FACS into subsets, and re-stimulated in vitro with a combinations of LPS, 
CPG, and anti-CD40 for 48 hours. After 48 hours of culture, supernatants were 
collected for ELISA. T2-MZP B cells show no difference in the capacity to 
secrete IL-10 between those obtained from naïve and tolerant mice (Figure 5.5 
B). These results suggest that IL-10 production is not associated with the ability 
of T2-MZP B cells (isolated from tolerant mice) to prolong allograft survival.  
Besides IL-10 expression, we also investigated the expression of CD80, CD86 
and TIM-1 on T2-MZP B cells isolated from tolerant mice. Here, B cells were 
magnetically purified from the spleens of either from B6 mice tolerised to B6 Kd 
skin graft at day 14 post-transplant, or from naïve B6 mice. The expression of 
CD80, CD86 and TIM-1 on B cell subsets was then determined by flow 
cytometry. T2-MZP B cells isolated from tolerant mice showed no differences in 
CD80 expression compared to control (naïve mice), however CD86 expression 
was significantly decreased in T2-MZP B cells from tolerant mice compared to 
naive T2-MZP B cells (Figure 5.5 C & D). On the other hand, the percentage of 
T2-MZP B cells expressing TIM-1 was significantly higher among T2-MZP B 
cells isolated from tolerant mice compared to naïve mice (Figure 5.5 E). 
However, TIM-1 was also significantly increased within MZ B cells, and showed 
a trend of higher expression in FO and T1 subsets (B cell subsets that do not 
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prolong allograft survival) (Figure 5.5 E). This would suggest that TIM-1 is not a 
marker of regulatory B cells in this model. 
In summary, we report for the first time an experimental mouse model of 
transplant tolerance that is associated with an increase in T2-MZP B cells. We 
demonstrated that adoptive transfer of these B cells was able to prolong skin 
graft survival suggesting a direct regulatory role for this subset in 
transplantation. In contrast to T2-MZP B cells isolated from tolerised mice, T2-
MZP B cells isolated from naïve mice were not able to prolong graft survival. 
Finally T2-MZP B cells isolated from tolerised mice downregulate B7 co-
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Figure	  5.5	  T2-­‐MZP	  B	  cells	  from	  B6.Kd	  DST	  +	  MR1	  tolerised	  B6	  mice	  do	  not	  upregulate	  the	  expression	  of	  IL-­‐10	  or	  Tim-­‐1+,	  but	  downregulate	  B7	  expression	  in	  vivo.	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Discussion 	  
In humans, maintenance of an immature transitional B cell population has been 
associated with both spontaneous tolerance to renal transplants as well as 
remission from systemic lupus erythematosus following B cell depletion 
[55,56,315]. Here we report for the first time an experimental mouse model of 
transplant tolerance that is similarly associated with an increase in T2-MZP B 
cells. We demonstrate that adoptive transfer of these B cells is able to prolong 
skin graft survival suggesting a direct regulatory role for this subset in 
transplantation. In contrast to T2-MZP B cells isolated from tolerised mice, T2-
MZP B cells isolated from naïve mice were not able to prolong graft survival. 
Finally T2-MZP isolated from tolerised mice down-regulated B7 co-stimulatory 
molecules, and suppressed T cell TNFα production in vitro. 
In the present chapter, we have shown that transplant tolerance is induced via 
DST plus MR1 only in B6 mice, but not uMT mice or B6 mice treated with MR1 
alone (Figure 5.1 A). Here, the level of allo-IgG antibodies in the serums of both 
allograft recipients B6 and uMT mice that was treated with DST plus MR1 show 
the same significant drop compared to controls (Figure 5.1 B). These results 
suggest that B cells are necessary for the establishment of DST + MR1 induced 
tolerance, and that no absolute correlation between graft rejection and IgG 
alloantibody production as none of the mice receiving MR1 treatment alone had 
detectable serum anti-Kd IgG even though they had rejected the graft. This 
result supports the findings of Sagoo et al and Newell et al. in man [55,56]. 
They found that the difference between tolerant and non-tolerant transplant 
recipients was in the number of B cells in the periphery and the expression of 
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genes that encoded for the variable region segment of the Ig light chain. 
Therefore, they called it “B-cell signature” and suggested that these genes 
could help in selecting transplant recipients who should receive 
immunosuppressive, from those who should not [55,56]. Although B cells have 
been primarily thought of as the source of alloantibodies that activate 
complement and varieties of effector cells [281], the presence of antibodies may 
simply be an indicator for B cell involvement in antibody-independent 
mechanisms [66]. This result also agrees with published data that B cells do not 
influence the immune response solely through the production of antibodies, but 
also via cytokine production or by presenting antigens [66]. 
In lupus model, it was observed that T2-MZP B cells absolute number was 
decreased during the disease [149]. Here, a significant expansion only in 
splenic T2-MZP and MZ B cells, but not FO or T1 B cells, was observed in mice 
that have been rendered tolerant via DST + MR1 treatment (Figure 5.2). 
Furthermore, T2-MZP B cells, but not MZ, T1 or FO B cells, isolated from 
tolerised mice at day 12 prolonged allograft survivals (Figure 5.3 A). This result 
confirms previous reports in autoimmunity, in which the adoptive transfer of B 
cells with T2-MZP B cells phenotype have protected from the disease 
[146,149]. However, in our model only T2-MZP B cells isolated from tolerised 
mice improved the allograft skin survival, but not the same subset when isolated 
from naïve mice (Figure 5.3 B). This result suggest that tolerising the mice with 
DST + MR1 has primed T2-MZP B cells in vivo to exert their regulatory function. 
It is possible that tolerising the mice via anti-CD40 ligand mAbs and donor 
splenocytes transfusion has produced activated tolerogenic T cells or Tregs that 
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interact and activate B cells in particular T2-MZP B cells to exert their regulatory 
function. This hypothesis can be confirmed by isolating T cells and Tregs from 
tolerised mice and co-culturing them with B cell subsets isolated from naïve B6 
mice, and studying how could the interaction between these cells could 
functionally influence the B cells, in particular, T2-MZP B cells, by re-culturing 
the induced B cell subsets with allo-DCs activated CD4+ T cells. 
Interestingly, although adoptive transfer of tolerised T2-MZP B cells does 
reduce the level of alloantibody detectable in the serum of graft recipients 
compared to controls, there was not a correlation between graft rejection and 
alloantibody production (Figure 5.3). Although prolongation of graft survival was 
observed only when mice were treated with T2-MZP B cells we found that 
alloantibody was reduced in the serum of mice treated with T2-MZP, MZ or T1 
B cells (figures 5.3 A & C). While in all cases where high levels of alloantibody 
are produced we see rejection, the converse is not true; we see rejection in the 
absence, or with low levels, of alloantibody. Thus, alloantibody production may 
not be the driving force behind rejection in this model. Alternatively alloantibody 
production may be more sensitive to regulation and both T1 and MZ B cells 
isolated from tolerised mice may possess some regulatory capacity. 
Beside the ability of T2-MZP B cells isolated from tolerised mice to prolong the 
allograft skin survival, they were the only B cell subset capable of inhibiting 
TNF-α expressing CD4+ T cells in vitro (Figure 5.4). Confirming the regulatory 
role that T2-MZP B cells can provide. 
In terms of regulatory function most previous studies on Breg cells in mice and 
humans have focused on their ability to produce IL-10 [256,257]. Moreover, IL-
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10 expression was necessary for TIM-1+ B cells to prolong MHC mismatched 
islet allograft survival [173, 316]. Here, we examined the expression of IL-10 
mRNA in B cell subsets isolated from tolerised mice at different time points post 
transplant, as well as IL-10 production by (ELISA) B cell subsets isolated from 
tolerised mice and activated with LPS plus anti-CD40 mAbs and CPG plus anti-
CD40 mAbs. The results showed that there is no significant increase in the 
expression of IL-10 mRNA in T2-MZP B cells at any time point (Figure 5.5 A). In 
addition, there was no significant difference in IL-10 production between any of 
the in vitro activated T2-MZP B cells isolated from tolerant and naïve mice 
(Figure 5.5 B). Finally, the finding that tolerised T1 B cells significantly 
upregulated IL-10 mRNA transcription compared to naïve T1 B cells further 
suggests IL-10 is not primarily responsible for prolongation of graft survival as 
adoptive transfer of T1 B cells was unable to delay rejection (Figure 5.3 A). 
However, although IL-10 production has defined Breg cells in the field of 
autoimmunity it is not as definitively associated with tolerance in investigations 
of transplantation [56,55,317,318]. Studies that have reported an association of 
B cells with tolerance to kidney transplants in humans did not report an 
association with IL-10 mRNA transcription [56,55,317]. In mice, studies of the 
capacity of anti-CD45RB monotherapy to induce tolerance to cardiac allografts 
reported that, while this tolerance protocol is dependent on the presence of B 
cells, IL-10 production by B cells was in fact counter-regulatory and IL-10 
neutralization improved graft outcome [318]. The role of IL-10 in B cell function 
in our transplant model needs to be adequately elucidated. Adoptive transfer of 
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IL-10-/- T2-MZP B cells tolerised in vivo with DST + MR1 into a second allograft 
recipient mice can completely rule out the role of IL-10 in our model. 
To explore other possible mechanisms involved in the protective role of T2-MZP 
B cells, we studied the expression of CD80, CD86 and TIM-1 on B cell subsets 
isolated from the spleens of tolerised and naïve mice at day 14 post transplant. 
There were no significant differences in the expression of CD80 molecules on 
T2-MZP B cells isolated from naïve or tolerised mice (Figure 5.5 C). However, 
Figure 5.5 D show that there was a significant drop in CD86 molecule on T2-
MZP B cells isolated from tolerised mice compared to those isolated from naïve 
mice (Figure 5.5 D). It is well known that B cells deliver essential signals for the 
activation and proliferation of both CD4 T cells and memory T cells through 
CD80 and CD86 [134,135,136]. An experiment that was performed using mice 
that lack the expression of CD80 and CD86 on B cells, in an arthritis model, 
demonstrated that the expression of CD80 and CD86 by B cells is needed for 
auto-reactive T cell proliferation and activation [136]. In vitro, re-activation of 
CD4+ T cells obtained from mice that express B cells deficient of CD80/CD86 
molecules with cartilage antigen resulted in less proliferation in CD4+ T cells 
compared to the WT CD4+ T cells [136]. The fact that CD86 binds with low 
affinity to CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) and with high affinity to 
CD28 [291] suggest that the significant drop in CD86 molecules expression on 
T2-MZP B cells compared to control has in turn affected the level of T cell 
activation. It might be helpful to test this theory by the adoptive transfer of 
CD86-/- T2-MZP B cells isolated for tolerised mice into all-graft skin recipients.  
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In the context of transplantation, TIM-1+ B cells, generated following treatment 
of mice with a low affinity/blocking anti-TIM-1 antibody, have recently been 
described to be able to prolong MHC mismatched islet allograft survival 
following adoptive transfer [173]. It is not clear whether TIM-1 is associated with 
Breg function in our model. We investigated the expression of TIM-1 on B cells 
isolated from DST + MR1 tolerised mice. We found that TIM-1 was expressed 
across all tolerised B cell subsets and, while it was upregulated on T2 B cells 
following tolerisation, there was still a lower percentage of TIM-1+ T2 than any 
other subset (Figure 5.5 E). In a recent paper, Qian et al. have reported an 
induction of Breg cells by regulatory dendritic cells and similarly to us they have 
not found an increase in TIM-1 expression by the B cells [319]. These results 
may suggest that there are a number of possible Breg cell phenotypes each 
specific for a particular mouse models. 
In summary, we have demonstrated that DST + MR1 tolerised T2-MZP B cells 
have a direct effect on CD4+ T cell activation in vitro and in vivo. We 
hypothesize that MR1 + DST activates and expands T2-MZP B cells that in the 
context of diminished CD86 costimulation, prevent allospecific T cell activation. 
The B cell signature, and preserved T2-MZP B cell compartment, of 
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Conclusion 
In this thesis, I have shown that B cells exert their regulatory role in prolonging 
skin transplant survival only when they were educated and primed in vivo. The 
experiments in this thesis have shown that B cells, in particular T2-MZP B cells 
have an inhibitory effect in vivo and in vitro either after being isolated from 
tolerised mice or obtained from mice kept under non-hygienic conditions. The 
exact mechanisms that lead to this priming are unclear, and whether the same 
mechanisms apply for both conditions is also not clear. Different possibilities for 
each situation have been discussed at the end of the results chapter. Although 
the two systems that have been used in this thesis leads to the same results, 
where B cells suppressed TNF-α expressing CD4+ T cells in vitro and 
prolonged skin graft survivals, the process of priming T2-MZP B cells in vivo is 
different. T2-MZP B cells isolated from mice kept under non-hygienic conditions 
might be primed through their interaction with gut microbiota via engagement of 
TLRs. In the mice rendered tolerant, T2-MZP B cells may be induced to have a 
regulatory function by interacting in the tolerant mice with regulatory T cells. 
However, further work is necessary to understand the differences between the 
two ways that Bregs are induced. An interesting preliminary result has shown 
that B cells obtained from Gal-1-/- mice rendered tolerant using MR1 and DST 
are suppressive, further emphasizing the difference between the two ways in 
which B cells can be induced to become regulatory.  
The important role that hygiene plays in inducing B cell regulatory function 
brings the CV mouse model described here closest to the situation in man. 
Also, my results suggest that T2-MZP B cells are regulatory in transplantation, 
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thus one of the reasons rituximab may have resulted in a higher incidence of 
graft rejection is because of the depletion of regulatory B cells.  
Although alloantibodies have been known for their central role in provoking 
transplant rejection through complement-dependent and complement-
independent pathways [63], the results in this thesis suggest that there is not an 
absolute correlation between graft rejection and IgG alloantibody production.  
I have also established that IL-10 is not the major mechanism involved in T2-
MZP B cell regulatory functions, in contrast to what has previously been 
reported in autoimmunity [146,149]. It is possible that in transplantation T2-MZP 
B cells exert their regulatory function through the involvement of other cytokines 
or ligands, however, further investigation is required to clarify this point. 
Finally, I have shown that Gal-1 is essential for T2-MZP B cell regulatory 
function when isolated from mice housed in the CV facility. The mechanism 
behind the regulatory role of Gal-1 during transplantation remains to be 
investigated. However, as mentioned earlier in the discussion there might be 
more than one possible mechanism: for instance the effect of Gal-1 on B cell 
development as there was a significant difference in the percentages of T2-
MZP B cells between WT and Gal-1-/- mice. Moreover, Gal-1 might be required 
in T2-MZP B cells signaling pathways, as there were significant differences in 
NF-κB translocation, P38 and ERK phosphorylation between Gal-1-/- and WT B 
cells. In addition, Gal-1 production by T2-MZP B cells might be essential in 
shifting T cell responses from Th1 and Th17 into Th2. It might also be due to 
the involvement of Gal-1 in the immunological synapse between T and B cells, 
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as Gal-1 has been reported to bridge linking cells to each other and cells to 
their extracellular matrixes [174]. 
Linked to one of the possible mechanisms that explain the loss of regulatory 
ability when Gal-1 is absent in B cells, I have for the first time identified the 
importance of Gal-1 expression in TLR-4 and 9 signaling in B cells. Here, I 
found that Gal-1 up regulates NF-κB and P38 pathways, and down regulates 
ERK pathway in B cells in response to TLR-9 ligand. This regulation provided 
by Gal-1 is essential in controlling IL-10 production in B cells. However, in the 
case of TLR-4 ligation, the high IL-10 production was only correlated with the 
decrease in NF-κB translocation, but no obvious involvement with ERK or P38. 
These findings suggest that Gal-1 plays different regulatory role in controlling 
IL-10 production by activated B cells depending on the TLR that has been 
ligated. However, how Gal-1 provides this role and where Gal-1 is involved in 
these pathways still needs to be investigated.  
As mentioned earlier in the Introduction Chapter (section1.2.1), T2-MZP B cells 
are immature cells that might, upon adoptive transfer or co-culturing in vitro with 
T cells, mature into other subsets. However, its difficult to prove whether T2-
MZP Breg cells represent a stage of B cell maturation or a subpopulation of B 
cells on their own. Therefore, thinking of a therapeutic use of these cells to 
induce tolerance is at this stage difficult. The expansion of T2-MZP B cells in 
vitro for adoptive cell therapy would be a complicated process unless the right 
stimuli and conditions are established to yield and maintain regulatory B cells 
with a T2-MZP B cells phenotype and properties. Alternatively strategies should 
be applied to increase the number of these cells directly in vivo. Whether 
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cellular therapy with Tregs, which is already in use in the clinic, can achieve the 
expansion of Bregs in vivo will be an important question to investigate when 
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